| Section | Name | Details |
| 24.01 | Palivizumab IM Syringe Synagis® | |
| 05.03.01 | Abacavir Ziagen® | |
| 05.03.01 | Abacavir and Lamivudine Kivexa® | Tablets |
| 05.03.01 | Abacavir and Lamivudine and Zidovudine Trizivir® | |
| 06.01.01.02 | Abasaglar® Insulin glargine | 3mL pre-filled disposible pen (KwikPen®) 3mL cartridge **First line insulin glargine in NEW PATIENTS** |
| 10.01.03 | Abatacept | Intravenous infusion |
| 24.03 | Abatacept IV Infusion | |
| 02.09 | Abciximab | Injection |
| 04.10.01 | Acamprosate | Gastro-resistant tablets Only in conjunction with specialist service |
| 06.01.02.03 | Acarbose Glucobay® | Tablets |
| 02.08.02 | Acenocoumarol Sinthrome® | Tablets |
| 02.08.02 | Acenocoumarol Sinthrome® | Tablets |
| 11.06 | Acetazolamide Diamox® | Tablets Sustained release capsules Injection  Ophthalmic specialist initiation only |
| 12.01.01 | Acetic Acid 2% Earcalm ® | Ear Spray |
| 11.08.02 | Acetylcholine Chloride | Intraocular irrigation |
| 05.03.02.01 | Aciclovir | Tablets Suspension Intravenous Infusion |
| 11.03.03 | Aciclovir | Eye ointment |
| 13.10.03 | Aciclovir Zovirax® | Cream |
| 13.05.02 | Acitretin Neotigason® | Capsules Dermatology only |
| 03.01.02 | Aclidinium Eklira Genuair® | Inhaler 400 micrograms/dose |
| 03.01.04 | Aclidinium / Formoterol Duaklir® Genuair | Combination LABA/LAMA inhaler |
| 06.01.01.01 | Actrapid® | 10ml vial |
| 01.05.03 | Adalimumab Humira® | |
| 10.01.03 | Adalimumab | Subcutaneous Injection |
| 13.05.03 | Adalimumab Humira® | |
| 09.05.01.01 | Adcal® | Chewable tablets |
| 05.03.03.01 | Adefovir Dipivoxil Hepsera® | |
| 02.03.02 | Adenosine Adenocor® | Injection Infusion |
| 02.07.03 | Adrenaline / Epinephrine | Injection |
| 03.04.03 | Adrenaline / epinephrine |  Injection (IM/SC)Injection (IV) Extreme caution Intravenous adrenaline should only be given by those experienced in its use, in a setting where patients can be carefully monitored. See BNF for more information. Intramuscular injection for self-administration (auto-injector) (EpiPen®, Jext®)It is advisable to prescribe adrenaline auto-injector by brand to avoid confusion. |
| 11.08.02 | Aflibercept Eylea® | Intravitreal injection Ophthalmic consultant only Use as per GMMMMG Macular Drugs Pathway |
| 04.03.04 | Agomelatine | Agomelatine may have a role for specialist initiation, but only in those patients with severe depression who have already failed on all classes of antidepressant therapies. |
| 05.05.01 | Albendazole | Tablets unlicensed |
| 05.05.03 | Albendazole | Tabletsunlicensed |
| 05.05.04 | Albendazole | See section 5.5.1. |
| 05.05.07 | Albendazole | Tabletsunlicensed |
| 05.05.08 | Albendazole | Tabletsunlicensed |
| 08.02.03 | Alemtuzumab MabCampath® | Concentrate for intravenous infusion Specialist use only Patient access scheme may be available. Patient access and monitoring form available from pharmacy. |
| 24.03 | Alemtuzumab IV Infusion | |
| 24.03 | Alemtuzumab SC Injection | |
| 06.06.02 | Alendronic Acid | 70mg tablets (once weekly preparation) |
| 09.06.04 | Alfacalcidol One-Alpha® | Capsules Oral Solution For maintenance, not for treatment. Frequency of plasma calcium monitoring should be determined by secondary care clinicians and communicated to primary care |
| 15.01.04.03 | Alfentanil Rapifen® | |
| 07.04.01 | Alfuzosin | M/R tablets |
| 03.04.01 | Alimemazine | Tablets Oral Solution On formulary for paediatric use only |
| 02.12 | Alirocumab Praluent® | Pre-filled syringe Pre-filled pen For patients with latex allergy or intolerance to evolocumabOnly as per NICE TA393. Requires completion of Blueteq form prior to initiation. Available via Homecare providers. |
| 13.05.01 | Alitretinoin Toctino® | Capsules Dermatology (Salford Royal) only |
| 10.01.04 | Allopurinol | Tablets |
| 06.01.02.03 | Alogliptin Vipidia® | Tablets |
| 09.06.05 | Alpha Tocopheryl Acetate | Oral suspension |
| 13.09 | Alphosyl 2 in 1® Coal Tar Extract 5% (Alcoholic) | Shampoo |
| 07.04.05 | Alprostadil | Caverject® intracavernosal injection MUSE® urethral application |
| 02.10.02 | Alteplase Actilyse® | Actilyse InjectionActilyse Cathflo 2mg (for thrombolytic treatment of occluded central venous access devices)is restricted to NMGH Renal Unit only; Approved for pulmonary embolism, acute ischaemic stroke (FGH only) and thrombolysis in acute limb ischaemia. Alteplase is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication if: |
| 13.12 | Aluminimum Chloride Hexahydrate 20% in Alcoholic Base Anhydrol Forte® or Driclor® | |
| 09.05.02.02 | Aluminium Hydroxide Alu-Cap® | 475mg capsules |
| 01.02 | Alverine Citrate Spasmonal® | |
| 04.09.01 | Amantadine Hydrochloride | Capsules Syrup |
| 24.01 | Ambisome IV Infusion | |
| 24.01 | Ambisome IV Syringe 1mg/ml | |
| 05.01.04 | Amikacin | Injection Can only be prescribed for intravenous use following discussion with the Consultant Microbiologist or ID Physician |
| 02.02.03 | Amiloride | Tablets Liquid |
| 13.08.01 | Aminolevulinic acid Metvix | Cream Dermatology Only |
| 03.01.03 | Aminophylline | Modified release tablets  Injection |
| 02.03.02 | Amiodarone | Tablets Infusion Injection (emergency use only) Specialist initiation only |
| 04.02.01 | Amisulpride | Tablets Oral solution RED when prescribed for new patients with dementia or other unlicensed indications |
| 04.03.01 | Amitriptyline | Tablets Oral solution |
| 04.07.03 | Amitriptyline | Tablets Oral solution |
| 06.01.05 | Amitriptyline | Tablets Oral solution unlicensed |
| 02.06.02 | Amlodipine | Tablets |
| 13.10.02 | Amorolfine Loceryl® | Dermatology Only |
| 05.01.01.03 | Amoxicillin | Capsules Oral Suspension Sachets Injection |
| 05.02.03 | Amphotericin AmBisome® | Intravenous Infusion Prepared by pharmacy aseptics during working hours. Liaise with pharmacy. |
| 24.03 | Amsacrine IV Infusion | |
| 09.01.04 | Anagrelide Xagrid® | Capsules |
| 08.03.04.01 | Anastrozole Arimidex® | Tablets |
| 11.04.02 | Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin® | Eye drops |
| 13.08.01 | Anthelios® Melt In Cream SPF50 | Cream Dermatology Only |
| 14.05.03 | Anti-D (Rh0) Immunoglobulin | |
| 09.01.03 | Anti-human thymocyte immunoglobulin (rabbit) Thymoglobuline® | |
| 01.07.01 | Anusol® | Cream Suppositories |
| 01.07.02 | Anusol-HC® | Ointment Suppositories |
| 06.01.01.01 | Apidra® Insulin Glulisine | 3ml cartridge (via ClikSTAR® or Autopen® 24) 3ml pre-filled disposable pen (SoloStar®) |
| 02.08.02 | Apixaban Eliquis | Tablets |
| 02.08.02 | Apixaban Eliquis | Tablets |
| 04.09.01 | Apomorphine Injection | Initiation on the recommendation of a movement disorder specialist only |
| 11.06 | Apraclonidine Iopidine® | Eye drops Ophthalmic consultant initiation only: Apraclonidine can be used long term for certain complex glaucoma cases where surgery is high risk. See also section 11.8. 1% - unlicensed use |
| 11.08.02 | Apraclonidine Iopidine® | 0.5% Eye drops 1% Single-use eye drops Apraclonidine 1% is licensed for control or prevention of postoperative elevation of intraocular pressure after anterior segment laser surgery. See also section 11.06. Ophthalmic specialist initiation only |
| 10.01.03 | Apremilast Otezla® | Tablets |
| 13.02.01.01 | Aqueous Cream BP | |
| 06.02.02 | Aqueous Iodine Oral Solution Lugol's | Oral solution |
| 01.06.03 | Arachis Oil Enema | |
| 04.02.01 | Aripiprazole | Tablets Orodispersible tablets Oral solution Injection (IM) RED when prescribed for new patients with dementia or other unlicensed indications |
| 04.02.02 | Aripiprazole Abilify Maintena® | Vial |
| 24.03 | Arsenic Trioxide IV Infusion | |
| 05.04.01 | Artemether with lumefantrine Riamet® | Tablets |
| 05.04.01 | Artesunate | Injectionunlicensed |
| 09.06.03 | Ascorbic Acid | Tablets |
| 04.02.03 | Asenapine | Sublingual tablets Pennine Care: may be considered third line for inpatients who have failed to respond or failed to tolerate existing therapies. |
| 02.09 | Aspirin (antiplatelet) | Dispersible tablets Gastro-resistant (enteric coated) tablets (only for patients established on this product) Tablets See information above. Low dose aspirin prophylaxis should not routinely be initiated for primary prevention. Enteric-coated aspirin tablets are not recommended. There is no convincing evidence that at a daily dose of 75mg using enteric coated rather than soluble aspirin reduces the risk of gastrointestinal bleeding. (Ref: Drug Ter Bull. Jan 1997, p7-8). |
| 05.03.01 | Atazanavir Reyataz® | |
| 05.03.01 | Atazanavir and Cobicistat Evotaz® | Tablets |
| 02.04 | Atenolol | Tablets Syrup Injection |
| 04.04 | Atomoxetine | Mental health services only |
| 02.12 | Atorvastatin | Tablets
|
| 07.01.03 | Atosiban Tractocile® | Not to be initiated at Pennine Acute Trust |
| 05.04.08 | Atovaquone | Oral suspension |
| 15.01.05 | Atracurium Besilate | |
| 15.01.03 | Atropine | |
| 11.05 | Atropine Sulphate | 0.5% eye drops 1% eye drops 1% single-use eye drops (Minims®) |
| 13.02.01 | Aveeno® | Cream Dermatology only |
| 24.03 | Azacitadine SC Injection | |
| 01.05.03 | Azathioprine | Tablets |
| 08.02.01 | Azathioprine | Tablets Injection
|
| 10.01.03 | Azathioprine | Tablets |
| 13.05.03 | Azathioprine | Tabletsunlicensed indication (severe refractory eczema) |
| 05.01.05 | Azithromycin | Capsules Tablets Oral Suspension |
| 11.03.01 | Azithromycin Azyter® | Eye drop solution in single-dose container For use in paediatric conjunctivitis - see policy |
| 05.01.02.03 | Aztreonam | Injection Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 09.06.02 | B Vitamins, High Potency Pabrinex® | Intravenous Injection Intramuscular Injection |
| 10.02.02 | Baclofen | Tablets Oral solution |
| 13.02.01.01 | Balneum Plus Bath Oil | |
| 13.02.01 | Balneum® Plus cream | Cream |
| 01.05.01 | Balsalazide Sodium Colazide® | Capsules Specialist initiation only |
| 10.01.03 | Baricitinib Olumiant® | Tablets |
| 24.02 | BBraun Nutriflex Lipid Peri 1250 | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Lipid Peri 1875 | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Lipid Peri 2500 | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Lipid Plus 2500 | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Lipid Special 1250 | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Lipid Special 1875 | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Lipid Special 1875 EF | Additions of electrolytes available on request |
| 24.02 | BBraun Nutriflex Special 1500 | Additions of electrolytes available on request |
| 07.04.04 | BCG (Bacillus Calmette-Guerin) | Bladder instillation |
| 08.02.04 | BCG bladder instillation OncoTICE® | Specialist use only |
| 14.04 | BCG vaccine diagnostic agent Tuberculin PPD | |
| 14.04 | BCG vaccine Intradermal | |
| 03.02 | Beclometasone Qvar® | Metered Dose Inhaler (MDI) Easi-breathe® Autohaler®  Not licensed for use in paediatrics. |
| 03.02 | Beclometasone Clenil Modulite® | Metered Dose Inhaler (MDI) |
| 03.02 | Beclometasone / formoterol / glycopyrronium Trimbow® | Metered dose inhaler (MDI) Combination ICS/LABA/LAMA inhaler |
| 03.02 | Beclometasone and formoterol Fostair® | Metered dose inhaler (MDI) Combination ICS/LABA inhaler Fostair® contains an extra-fine formulation of beclomethasone and is more potent than traditional CFC-containing beclomethasone inhalers - check dose. First-line MDI for patients with COPD who cannot use dry powder inhalers or would prefer a metered-dose inhaler. |
| 12.02.01 | Beclometasone Dipropionate | Nasal Spray |
| 05.01.09 | Bedaquiline Sirturo® | TabletsCan only be prescribed after discussion with an ID physician |
| 03.04.02 | Bee and Wasp Allergen Extracts Pharmalgen® | Subcutaneous injection Specialist Use Only |
| 24.03 | Bendamustine IV Infusion | |
| 02.02.01 | Bendroflumethiazide | Tablets Not first line for hypertension (see NICE CG127: Hypertension). Patients with stable and controlled blood pressure currently taking bendroflumethiazide can continue treatment. |
| 12.03.01 | Benzocaine | Anaesthetic gel |
| 13.06.01 | Benzoyl Peroxide 2.5 - 10% | Gel Lotion |
| 13.06.01 | Benzoyl Peroxide with antimicrobials Quinoderm® | Cream |
| 12.03.01 | Benzydamine Difflam® | Mouthwash Oromucosal Spray |
| 05.01.01.01 | Benzylpenicillin | Injection |
| 04.06 | Betahistine | Tablets |
| 04.06 | Betahistine Dihydrochloride | |
| 06.03.02 | Betamethasone | Injection Soluble tablets |
| 11.04.01 | Betamethasone | Eye/ear/nose drops Eye ointment |
| 13.04 | Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic® | Ointment Scalp Application |
| 13.04 | Betamethasone (as Valerate) 0.025% Betnovate-RD® | Cream Ointment |
| 13.04 | Betamethasone (as Valerate) 0.1% Betnovate Scalp® | Scalp application |
| 13.04 | Betamethasone (as Valerate) 0.1% Non-proprietary or Betnovate® | Cream Ointment |
| 13.04 | Betamethasone (as Valerate) 0.1% with Clioquinol Non proprietary or Betnovate-C® | Cream Ointment |
| 13.04 | Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet® | Cream |
| 13.04 | Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% Non-proprietary or Betnovate-N® | Cream Ointment |
| 12.01.01 | Betamethasone 0.1% with Neomycin 0.5% drops Betnesol N® | Ear/eye/nose drops |
| 12.01.01 | Betamethasone 0.1% with Neomycin 0.5% drops Betnesol N® | Ear/eye/nose drops |
| 13.04 | Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® | Cream |
| 12.01.01 | Betamethasone drops | Ear/eye/nose drops |
| 12.02.01 | Betamethasone drops | Eye/ear/nose drops |
| 13.04 | Betamethasone Valerate 0.1% Scalp Application Betacap® | Scalp application |
| 11.04.01 | Betamethasone with Neomycin | Eye/ear/nose drops |
| 11.06 | Betaxolol | Eye drops Unit dose eye drops |
| 11.08.02 | Bevacizumab intravitreal injection | Ocular injection Named-patient use only. For existing patients only. Ophthalmic consultant onlyunlicensed |
| 08.03.04.02 | Bicalutamide | Tablets |
| 11.06 | Bimatoprost Lumigan® | Eye drops Single-use eye drops |
| 11.06 | Bimatoprost with Timolol Ganfort® | Eye drops Single-use eye drops Combination products are licensed for once daily use where prostaglandin analogue alone is not adequate. Only use where patient has difficulty with compliance/administration. |
| 12.03.05 | Biotene Oralbalance® | Saliva replacement gel |
| 09.08.01 | Biotin | Tabletsunlicensed |
| 12.03.05 | BioXtra® | Gel |
| 01.06.02 | Bisacodyl | Tablets Suppositories |
| 02.04 | Bisoprolol | Tablets |
| 24.03 | Bleomycin IV Infusion | |
| 24.03 | Bortezomib SC Injection | |
| 04.09.03 | Botulinum Toxin Type A Botox® | |
| 04.09.03 | Botulinum Toxin Type A Dysport® | |
| 24.03 | Brentuximab IV Infusion | |
| 11.06 | Brimonidine Tartrate Alphagan® | Eye drops |
| 11.06 | Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® | Eye drops Combination products are licensed for use when beta blocker monotherapy does not provide adequate treatment. Only use where patient has difficulty with compliance/administration. |
| 11.06 | Brinzolamide Azopt® | Eye drops |
| 11.06 | Brinzolamide 1% with Timolol 0.5% Azarga® | Eye drops Only use combination products where patient has difficulty with compliance/administration. |
| 06.07.01 | Bromocriptine | Tablets Capsules |
| 01.05.02 | Budesonide Entocort® | C/R capsules Specialist initiation only: for treatment resistant terminal-ileal Crohn's disease |
| 03.02 | Budesonide | Dry powder inhaler (Easyhaler®, Pulmicort® Turbohaler) Respules |
| 03.02 | Budesonide and formoterol Symbicort® Turbohaler | Dry powder inhaler Combination ICS/LABA inhaler Not to be initiated, but can be continued in established patients |
| 03.02 | Budesonide and formoterol DuoResp® Spiromax | Dry powder inhaler Combination ICS/LABA inhaler |
| 02.02.02 | Bumetanide | Tablets Liquid Injection has been discontinued |
| 15.02 | Bupivacaine and Adrenaline | |
| 15.02 | Bupivacaine Hydrochloride | |
| 15.02 | Bupivacaine with Fentanyl | |
| 04.07.02 | Buprenorphine | Patches (BuTrans® or Transtec®) S/L tablets (Temgesic®) |
| 04.10.03 | Buprenorphine Subutex® | Sublingual tablets |
| 04.09.01 | Cabergoline | Tablets |
| 06.07.01 | Cabergoline | Tablets |
| 09.05.01.01 | Cacit® | Effervescent tablets |
| 13.03 | Calamine | Cream Lotion |
| 13.05.02 | Calamine and Coal Tar Ointment | Ointment |
| 09.05.01.01 | Calcichew® | Chewable tablets |
| 13.05.02 | Calcipotriol | Ointment Scalp solution To be commenced on advice of dermatology only |
| 13.05.02 | Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet® | Ointment Gel To be commenced on advice of dermatology only |
| 06.06.01 | Calcitonin (salmon) / Salcatonin | Injection |
| 09.06.04 | Calcitriol | Capsules For maintenance, not for treatment |
| 13.05.02 | Calcitriol 3micrograms/g Silkis® | Ointment To be commenced on advice of dermatology only |
| 09.05.02.02 | Calcium Acetate Phosex® | 1 gram tablets |
| 09.06.04 | Calcium and colecalciferol Calfovit D3® | Sachets |
| 09.06.04 | Calcium and Colecalciferol Calceos® | Chewable tablets |
| 09.05.02.02 | Calcium Carbonate Calcichew® | 500mg chewable tablets |
| 09.05.01.01 | Calcium Chloride 10% Injection | Injection |
| 05.04.07 | Calcium Folinate | |
| 05.04.07 | Calcium Folinate | Tablets Injection |
| 08.01 | Calcium Folinate | Tablets Injection |
| 09.05.01.01 | Calcium Gluconate 10% Injection | Injection |
| 13.02.01 | Calmurid® | Cream |
| 09.04 | Calogen | Dose calculated by dietitian |
| 06.01.02.03 | Canagliflozin Invokana® | Tablets |
| 02.05.05.02 | Candesartan | Tablets |
| 13.09 | Capasal® Shampoo | Shampoo |
| 05.01.09 | Capreomycin Capastat® | Intramuscular Injection Can only be prescribed following discussion with an ID physician |
| 06.01.05 | Capsaicin | Cream 0.075& |
| 10.03.02 | Capsaicin | 0.025% cream (adjunct in hand or knee osteoarthritis) 0.075% cream (postherpetic neuralgia and diabetic neuropathy) |
| 02.05.05.01 | Captopril | Tablets Oral solution unlicensed. For paediatric use onlyNot as per GMMMG for adults |
| 04.02.03 | Carbamazepine | Tablets M/R tablets Liquid Suppositories |
| 04.07.03 | Carbamazepine | Tablets M/R tablets Liquid Suppositories |
| 04.08.01 | Carbamazepine | Tablets M/R tablets Liquid Suppositories Ensure patients are maintained on a specific manufacturer's product / brand |
| 06.02.02 | Carbimazole | Tablets |
| 03.07 | Carbocisteine | Capsules Liquid |
| 11.08.01 | Carbomers | Eye drops Single-use eye drops Brand with lowest aquisition cost will be supplied. |
| 24.03 | Carboplatin IV Infusion | |
| 07.01.01 | Carboprost Hemabate® | Injection |
| 24.03 | Carfilzomib IV Infusion | |
| 11.08.01 | Carmellose | Eye drops Single-use eye drops Brand with lowest aquisition cost will be supplied. |
| 12.03.01 | Carmellose Sodium Orabase® | Oral paste |
| 12.03.01 | Carmellose Sodium Orahesive® | Powder |
| 09.08.01 | Carnitine Carnitor® | |
| 11.06 | Carteolol Teoptic® | Eye drops |
| 02.04 | Carvedilol | Tablets |
| 05.02.04 | Caspofungin Cancidas® | Intravenous Infusion Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 07.04.04 | Catheter Patency Solutions Solution R Uro-Tainer® | |
| 07.04.04 | Catheter Patency Solutions Sodium Chloride 0.9% Uro-Tainer® | |
| 13.02.02 | Cavilon®Film | Barrier PreparationObtained through SUPPLIES not pharmacy |
| 13.09 | Ceanel Concentrate® Shampoo | Shampoo |
| 05.01.02.01 | Cefalexin | Capsules Tablets Oral Suspension |
| 05.01.02.01 | Cefixime | Tablets Oral Suspension |
| 05.01.02.01 | Cefotaxime | Injection |
| 24.01 | Cefoxitin IV Infusion | 3gram Infusor |
| 05.01.02.01 | Ceftazidime | Injection |
| 24.01 | Ceftazidime IV infusion | 3gram ECLIPSE pump |
| 05.01.02.01 | Ceftriaxone | Injection |
| 24.01 | Ceftriaxone IV infusion | 50mg/mL |
| 05.01.02.01 | Cefuroxime Zinacef® | Injection Tablets Oral Suspension |
| 11.03.01 | Cefuroxime | Eye drops unlicensed special STORE IN FREEZER PRIOR TO USE. Once thawed, store in fridge for a maximum of 7 days. |
| 10.01.01 | Celecoxib Celebrex® | Capsules |
| 10.01.03 | Certolizumab Pegol | Subcutaneous Injection |
| 12.01.03 | Cerumol® | Ear drops Not on GMMMG Formulary |
| 03.04.01 | Cetirizine | Tablets Oral solution |
| 13.02.01 | Cetraben® | Cream |
| 13.10.05 | Cetrimide 0.5% Cream | Cream |
| 04.01.01 | Chloral Hydrate 500mg in 5mL | |
| 05.01.07 | Chloramphenicol | Injection (Oral preparations are non-formulary) |
| 11.03.01 | Chloramphenicol | Eye drops Eye ointment Single use eye drops (Minims®) |
| 04.10.01 | Chlordiazepoxide | Capsules |
| 11.03.01 | Chlorhexidine | Eye drops unlicensed special Used with propamidine for acanthamoeaba keratitis only |
| 12.03.04 | Chlorhexidine Gluconate | Mouthwash Dental gel Oral spray |
| 12.02.03 | Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® | Cream Contains PEANUT oil |
| 05.04.01 | Chloroquine | Tablets Syrup |
| 02.02.01 | Chlorothiazide | Suspension unlicensed Paediatric use only |
| 03.04.01 | Chlorphenamine | Tablets Oral Solution |
| 04.02.01 | Chlorpromazine | Tablets Oral solution Injection |
| 14.04 | Cholera vaccine Dukoral® | NMGH Travel Clinic only |
| 12.03.01 | Choline Salicylate Bonjela® Adult | Oral gel For over 16 years of age only |
| 06.05.01 | Chorionic Gonadotrophin Pregnyl® | Injection |
| 01.05.03 | Ciclosporin | Capsules (Neoral®) Concentrate for intravenous infusion (Sandimmun®) MUST be prescribed by brand |
| 08.02.02 | Ciclosporin | Capsules Oral solution Prescribe by brand. Do not switch between brands.Brands:
|
| 10.01.03 | Ciclosporin | Capsules Prescribe by brand |
| 13.05.03 | Ciclosporin | Capsules Oral Solution Must be prescribed by BRAND. (See Section 8.2.2.) |
| 05.03.02.02 | Cidofovir Vistide® | |
| 24.03 | Cidofovir IV Infusion | |
| 07.03.01 | Cilest® Ethinylestradiol 35 mcg / norgestimate 250 mcg | Standard strength preparation |
| 09.05.01.02 | Cinacalcet Mimpara® | Tablets Use is subject to a local shared-care agreement with the patient's GP (see link) |
| 04.06 | Cinnarizine | Tablets |
| 04.06 | Cinnarizine | |
| 05.01.12 | Ciprofloxacin | Tablets Oral Suspension Intravenous Infusion: requires microbiology/ID consultant approval, unless use is in line with antibiotic policy |
| 11.03.01 | Ciprofloxacin | Eye drops |
| 15.01.05 | Cisatracurium Nimbex® | |
| 24.03 | Cisplatin IV Infusion | |
| 04.03.03 | Citalopram | Tablets Oral drops |
| 24.03 | Cladribine IV Infusion | |
| 24.03 | Cladribine SC Injection | |
| 05.01.05 | Clarithromycin | Tablets Oral Suspension Intravenous Infusion |
| 24.01 | Clarithromycin IV Infusion | 500mg in 250mL sodium chloride 0.9% |
| 05.01.06 | Clindamycin | Capsules Injection |
| 05.04.07 | Clindamycin | Capsules Injection |
| 05.04.08 | Clindamycin | Capsules Injection |
| 07.02.02 | Clindamycin | Cream |
| 13.06.01 | Clindamycin 1% Dalacin T® | Topical solution |
| 13.06.01 | Clindamycin 1% Zindaclin® | Gel |
| 04.08.01 | Clobazam | Tablets Oral suspension |
| 13.04 | Clobetasol Propionate 0.05% Dermovate® | Cream Ointment Scalp Application |
| 13.04 | Clobetasol Propionate 0.05% Etrivex® | Shampoo Dermatology only |
| 13.04 | Clobetasone Butyrate 0.05% Eumovate® | Cream Ointment |
| 13.04 | Clobetasone butyrate 0.05% with Oxytetracycline and Nystatin Trimovate® | Cream |
| 24.03 | Clofarabine SC Injection | |
| 05.01.10 | Clofazimine | Capsules Can only be prescribed following discussion with an ID physician |
| 06.05.01 | Clomifene Citrate | Tablets Only indicated for patients in whom ovulatory dysfunction has been demonstrated and other causes of infertility have been excluded or adequately treated |
| 04.03.01 | Clomipramine | Capsules M/R tablets Included as first choice in the treatment of OCD only |
| 04.08.01 | Clonazepam | Tablets Injection |
| 02.05.02 | Clonidine Hydrochloride | Tablets |
| 02.09 | Clopidogrel | Tablets See information above. |
| 07.02.02 | Clotrimazole | Cream Pessary |
| 12.01.01 | Clotrimazole Canesten® | 1% solution |
| 13.10.02 | Clotrimazole 1% | Cream Solution Spray |
| 04.02.01 | Clozapine Clozaril® | Clozapine is only indicated for treatment resistant schizophrenia. Prescribers, pharmacies and patients must be registered with the relevant supplier’s patient monitoring service. |
| 04.02.01 | Clozapine Zaponex® | Clozapine is only indicated for treatment resistant schizophrenia. Prescribers, pharmacies and patients must be registered with the relevant supplier’s patient monitoring service. |
| 13.05.02 | Coal Tar 1% Lotion | Lotion |
| 13.05.02 | Coal Tar and Salicylic Acid in Unguentum M | To be commenced on advice of dermatology only |
| 13.05.02 | Coal Tar in Salicylic Acid Ointment | Ointment |
| 13.05.02 | Coal Tar in Yellow Soft Paraffin | 0.5% 1% 3% 5% 10% 15% 20% 25% |
| 13.05.02 | Coal Tar Paste | Paste |
| 02.02.04 | Co-amilofruse (amiloride and furosemide) | Tablets Although it is preferable to prescribe potassium-sparing diuretics and loop diuretics separately, the use of fixed combinations may be justified if compliance is a problem (BNF). |
| 02.02.04 | Co-amilozide | Tablets Although it is preferable to prescribe potassium-sparing diuretics and thiazide diuretics separately, the use of fixed combinations may be justified if compliance is a problem (BNF). |
| 05.01.01.03 | Co-Amoxiclav | Tablets Oral Suspension Injection Co-amoxiclav is only recommended as first line treatment in specific indications. Refer to Antibiotic Policy. The risk of acute liver toxicity is 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 and in males. The duration of treatment should not normally exceed 14 days. Co-amoxiclav is a recognised cause of Clostridium difficile infections and its use should be restricted. |
| 04.09.01 | Co-Beneldopa Madopar® | Capsules Dispersible tablets M/R capsules |
| 05.03.01 | Cobicistat Tybost® | Tablets Requires MDT discussion with ID team |
| 11.07 | Cocaine | Eye dropsunlicensed |
| 04.09.01 | Co-Careldopa Sinemet® | Tablets M/R tablets |
| 04.09.01 | Co-Careldopa and Entacapone Stalevo® | Tablets |
| 13.06.02 | Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) Dianette® |
Tablets |
| 13.09 | Co-Cyprindiol 2000/35 (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms) Dianette® |
Tablets |
| 01.06.02 | Co-danthramer | Capsules Strong capsules Suspension Strong suspension Specialist use: Palliative care only |
| 01.06.02 | Co-danthrusate | Capsules Suspension Specialist use: Palliative care only |
| 01.04.02 | Codeine | Tablets Oral solution |
| 03.09.01 | Codeine Linctus BP | Oral solution |
| 04.07.02 | Codeine Phosphate | Tablets Oral liquid |
| 10.01.04 | Colchicine | Tablets |
| 09.06.04 | Colecalciferol | Capsules Oral solution |
| 09.06.04 | Colecalciferol and Calcium Carbonate Calcichew-D3® | Chewable tablets |
| 09.06.04 | Colecalciferol and Calcium Carbonate Calcichew-D3® Forte | Chewable tablets |
| 09.06.04 | Colecalciferol and Calcium Carbonate Adcal-D3® | Chewable Tablets Caplets Effervescent Tablets |
| 01.09.02 | Colestyramine Questran Light® | |
| 02.12 | Colestyramine | Powder |
| 05.01.07 | Colistimethate | Intravenous injection Injection for nebulisation (Colomycin® brand) Powder for nebuliser solution GMMMG RAG status when nebulised:
|
| 10.03.01 | Collagenase Xiapex® | Intralesional injection Individual funding request is NOT required when used for Dupytren's contracture that is moderate in nature. Defined as: AND one of the following: OR OR First web contracture. For all other indications (e.g. Frozen Shoulder / Peyronie's Disease / any other use / non-moderate Dupytren's) an individual funding request is required. |
| 01.01.01 | Co-magaldrox suspension | |
| 09.02.02.01 | Compound Sodium Lactate Intravenous Infusion | 500ml bag 1 litre bag |
| 13.02.02 | Conotrane® | Cream |
| 05.01.08 | Co-trimoxazole | Tablets Oral Suspension Intravenous Infusion |
| 05.04.08 | Co-trimoxazole | See section 5.1.8. |
| 13.03 | Crotamiton Eurax® | Cream Lotion |
| 13.11.06 | Crystacide® Hydrogen Peroxide 1% | Cream |
| 13.11.02 | CX Antiseptic Dusting Powder® Chlorhexidine | |
| 09.01.02 | Cyanocobalamin | Tablets Only for use in those patients who are truly unable to tolerate injections and who are vegan or have a proven dietary deficiency. |
| 04.06 | Cyclizine | Tablets Injection |
| 04.06 | Cyclizine | Tablets Injection |
| 04.06 | Cyclizine | Tablets Injection |
| 04.06 | Cyclizine | Tablets Injection |
| 04.06 | Cyclizine | Tablets Injection |
| 11.05 | Cyclopentolate Hydrochloride | 0.5% and 1% eye drops 0.5% and 1% single-use eye drops (Minims®) |
| 10.01.03 | Cyclophosphamide | Tablets Injection |
| 24.03 | Cyclophosphamide IV Infusion | |
| 24.03 | Cyclophosphamide IV Injection | |
| 24.03 | Cyclophosphamide, Etoposide and Cisplatin IV Infusion | |
| 05.01.09 | Cycloserine | Capsules Can only be prescribed following discussion with an ID physician |
| 06.04.02 | Cyproterone Acetate | Tablets |
| 08.03.04.02 | Cyproterone Acetate | Tablets
|
| 24.03 | Cytarabine Intrathecal Injection | |
| 24.03 | Cytarabine IV Infusion | |
| 24.03 | Cytarabine IV Injection | |
| 24.03 | Cytarabine SC Injection | |
| 02.08.02 | Dabigatran Pradaxa® | Capsules Praxbind® (idarucizumab) is a specific reversal agent for dabigatran. This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. |
| 02.08.02 | Dabigatran Pradaxa® | Capsules Praxbind® (idarucizumab) is a specific reversal agent for dabigatran. This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. |
| 02.08.02 | Dabigatran Pradaxa® | Capsules Praxbind® (idarucizumab) is a specific reversal agent for dabigatran. This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. |
| 24.03 | Dacarbazine IV Infusion | |
| 05.03.03.02 | Daclatasvir Daklinza® | Tablets Requires MDT discussion with ID team |
| 02.08.01 | Danaparoid Orgaran® | Injection For prevention and treatment of thromboembolic disease in patients with a history of heparin-induced thrombocytopenia. |
| 06.07.02 | Danazol | Capsules |
| 10.02.02 | Dantrolene | Capsules |
| 15.01.08 | Dantrolene Sodium Dantrium Intravenous® | |
| 06.01.02.03 | Dapagliflozin Forxiga® | Tablets |
| 05.01.10 | Dapsone | Tablets |
| 05.04.08 | Dapsone | Tablets |
| 05.01.07 | Daptomycin | Intravenous Infusion Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 24.03 | Daratumumab IV Infusion | |
| 09.01.03 | Darbepoetin Alfa Aranesp® | Injection |
| 05.03.01 | Darunavir Prezista® | |
| 05.03.01 | Darunavir and Cobicistat Rezolsta® | Tablets |
| 05.03.03.02 | Dasabuvir Exviera® | Tablets Requires MDT discussion with ID team |
| 24.03 | Daunorubicin IV Infusion | |
| 24.03 | Daunorubicin liposomal IV Infusion | |
| 09.01.03 | Deferasirox Exjade® | Dispersible tablets PbR Excluded - commissioned by NHS England |
| 09.01.03 | Deferiprone Ferriprox® | Tablets PbR Excluded - commissioned by NHS England |
| 08.03.04.02 | Degarelix Firmagon® | Subcutaneous injection
|
| 05.01.09 | Delamanid Deltyba® | TabletsCan only be prescribed following discussion with an ID physician |
| 06.05.02 | Demeclocycline | Capsules See section 6.5.2 of BNF for details of dosage in SIADH unlicensed |
| 06.06.02 | Denosumab Prolia® | Injection |
| 06.06.02 | Denosumab XGEVA® | Injection |
| 13.02.01 | Dermol® | Cream Dermol 500 Lotion |
| 13.02.01.01 | Dermol® | |
| 13.02.01.01 | Dermol® 600 bath emollient | |
| 09.01.03 | Desferrioxamine Mesilate | Injection PbR Excluded- commissioned by NHS England |
| 15.01.02 | Desflurane Suprane® | |
| 06.05.02 | Desmopressin | Tablets Sublingual tablets Nasal Spray Injection |
| 04.06 | Dexamethasone | Tablets Oral solution Injection |
| 06.03.02 | Dexamethasone | Tablets Injection Oral solution |
| 10.01.02.02 | Dexamethasone | Injection |
| 11.04.01 | Dexamethasone | Eye drops Single use eye drops (Minims®) |
| 11.04.01 | Dexamethasone intravitreal implant Ozurdex® | Intravitreal injection Specialist use only |
| 12.01.01 | Dexamethasone with Antibacterial Otomize® | Ear Spray |
| 12.01.01 | Dexamethasone with Antibacterial Sofradex® | Eye/ear drops Not on GMMMG formulary |
| 11.04.01 | Dexamethasone with Antibacterials Sofradex® | Eye/ear drops |
| 11.04.01 | Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® | Eye drops Eye ointment |
| 04.04 | Dexamfetamine | |
| 08.01 | Dexrazoxane Savene® | Intravenous Infusion |
| 04.07.02 | Diamorphine | Injection |
| 04.01.02 | Diazepam | Tablets Oral solution Injection Rectal tubes |
| 04.08.02 | Diazepam | Injection (emulsion) Rectal tubes (rectal solution) Use diazepam injection as first-line alternative only if lorazepam injection not available |
| 10.02.02 | Diazepam | Tablets Oral solution |
| 15.01.04.01 | Diazepam | |
| 10.01.01 | Diclofenac | Suppositories Injection Diclofenac is contraindicated in patients with established: •ischaemic heart disease •peripheral arterial disease •cerebrovascular disease •congestive heart failure (New York Heart Association [NYHA] classification II–IV) Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking). |
| 11.08.02 | Diclofenac Voltarol® Ophtha | Eye drops Single use eye drops (Not on GMMMG formulary) |
| 05.03.01 | Didanosine Videx® | Tablets Capsules Only for patients already established on this treatment. |
| 05.05.06 | Diethylcarbamazine | Tabletsunlicensed |
| 08.03.01 | Diethylstilbestrol | Tablets |
| 02.01.01 | Digoxin | When switching from oral to intravenous digoxin, the intravenous dose should be approximately 70% of the oral dose. GMMMG does not recommend digoxin as first-line for rate control of atrial fibrillation in ambulant patients. For plasma concentration monitoring, blood should be taken at least 6 hours after a dose. |
| 02.01.01 | Digoxin specific antibody fragments Digifab® | See link for SPC |
| 04.07.02 | Dihydrocodeine | Tablets M/R tablets |
| 05.04.02 | Diloxanide Furoate | Tablets |
| 02.06.02 | Diltiazem | Standard tablets (60mg) Modified release tablets Modified release capsules Specify the brand when prescribing a diltiazem preparation (except for 60mg tablet). |
| 01.07.04 | Diltiazem Cream 2% | |
| 13.05.02 | Dimethyl fumarate Skilarence® | Tablets Dermatology only |
| 07.04.04 | Dimethyl Sulfoxide 50% Rimso-50® | Bladder instillation |
| 13.10.04 | Dimeticone Hedrin® | Lotion |
| 07.01.01 | Dinoprostone | Pessaries (Propess®) Vaginal Tablets (Prostin E2®) |
| 14.04 | Diphtheria antitoxin | Microbiology / ID recommendation only |
| 14.04 | Diphtheria with Hib, pertussis, poliomyelitis and tetanus Pediacel® | |
| 14.04 | Diphtheria with Hib, pertussis, poliomyelitis and tetanus Infanrix-IPV + Hib® | |
| 14.04 | Diphtheria with pertussis, poliomyelitis and tetanus Repevax® | |
| 14.04 | Diphtheria with poliomyelitis and tetanus Revaxis® | |
| 13.02.01 | Diprobase® | Cream Ointment |
| 02.09 | Dipyridamole | Tablets Modified Release Capsules Oral suspension See information above. |
| 02.09 | Dipyridamole and Aspirin Asasantin® Retard | Modified release capsules. See information above. |
| 11.99.99.99 | Disodium Edetate 0.37% | Eye lotion |
| 06.06.02 | Disodium Pamidronate | Concentrate for Intravenous Infusion Refer to Electrolyte Disturbances Guidelines for dosage in hypercalcaemia |
| 02.03.02 | Disopyramide | Capsules (Injection discontinued) |
| 04.10.01 | Disulfiram Antabuse® | Specialist initiation only |
| 13.05.02 | Dithranol Dithrocream® | Cream: 0.1%, 0.25%, 0.5%, 1%, 2%. |
| 13.05.02 | Dithranol in Zinc and Salicylic Acid in Lassar's Paste | Pasteunlicensed |
| 02.07.01 | Dobutamine | Concentrate for intravenous infusion (dilute before use). |
| 01.06.02 | Docusate Sodium | Capsules Oral suspension |
| 05.03.01 | Dolutegravir Tivicay ® | Tablets |
| 05.03.01 | Dolutegravir and Abacavir and Lamivudine Triumeq ® | |
| 01.02 | Domperidone | Tablets Suspension unlicensed indication Studies have shown that domperidone may be associated with a small increased risk of serious cardiac side effects. These risks may be higher in patients older than 60 years and in patients who receive daily oral doses of more than 30 mg.Domperidone should be used at the lowest effective dose for the shortest possible timeMaximum treatment duration should not exceed one weekDomperidone is contra-indicated in patients who are taking concomitant medication known to cause QT prolongation (such as ketoconazole and erythromycin) |
| 04.06 | Domperidone | Tablets Suspension Suppositories (unlicensed) |
| 04.11 | Donepezil | Tablets Orodispersible tablets Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
| 02.07.01 | Dopamine | Concentrate for intravenous infusion (dilute before use). |
| 02.07.01 | Dopexamine | Concentrate for intravenous infusion (dilute before use). |
| 03.07 | Dornase Alfa Pulmozyme® | nebuliser solution Must only be initiated within hospital for the treatment of cystic fibrosis. |
| 11.06 | Dorzolomide | Eye drops Unit dose eye drops |
| 11.06 | Dorzolomide 2% with Timolol 0.5% | Eye drops Unit dose eye drops Only use combination products when patient has difficulty with compliance/administration. |
| 13.02.01 | DoubleBase® | Gel |
| 03.05.01 | Doxapram | Intravenous injection May also be given by intravenous infusion (unlicensed) |
| 02.05.04 | Doxazosin | Tablets Doxazosin is a fourth-line hypertension management option. Modified release preparations of doxazosin are not approved by GMMMG. Consider converting any existing patients to standard release doxazosin, using the UKMi Medicines Q&A for guidance. |
| 07.04.01 | Doxazosin | Tablets |
| 07.04.04 | Doxorubicin | Bladder instillation Liaise with Pharmacy Aseptics for preparation of this product |
| 24.03 | Doxorubicin IV Infusion | |
| 24.03 | Doxorubicin IV Injection | |
| 05.01.03 | Doxycycline | Capsules Dispersible Tablets |
| 05.04.01 | Doxycycline | See section 5.1.3. |
| 13.06.02 | Doxycycline | Capsules Alternative choice for acne and rosacea |
| 13.02.02 | Drapolene® | Cream |
| 02.03.02 | Dronedarone Multaq® | Tablets Cardiologist/stroke physician initiation only Dronedarone should only be initiated as a second line treatment option for non-permanent atrial fibrillation after: Dronedarone is not recommended for patients with permanent AF. See attached guidance for more information. |
| 03.01.05 | Drug Delivery Device Volumatic® | |
| 03.01.05 | Drug Delivery Device AeroChamber Plus® | |
| 04.03.04 | Duloxetine Cymbalta® | |
| 04.07.03 | Duloxetine Cymbalta® | CapsulesDuloxetine may be considered as an option where other treatments have failed, or for a clear diagnosis of diabetic neuropathy. |
| 06.01.05 | Duloxetine Cymbalta® | Capsules |
| 07.04.02 | Duloxetine Yentreve® | Capsules For stress incontinence only |
| 13.08.01 | Dundee reflective sun creams Dundee Block® | Dermatology Onlyunlicensed |
| 06.04.02 | Dutasteride Avodart® | Tablets |
| 13.08.01 | E45 Sun Reflective Sunscreen® | Preparations with an SPF less than 30 should not be prescribed. |
| 13.02.01 | E45® Cream | Cream |
| 07.02.02 | Econazole | Cream |
| 02.08.02 | Edoxaban Lixiana® | Tablets |
| 02.08.02 | Edoxaban Lixiana® | Tablets |
| 05.03.01 | Efavirenz Sustiva® | |
| 13.09 | Eflornithine 11.5% Cream Vaniqa® | Dermatology only |
| 05.03.03.02 | Elbasvir/Grazoprevir Zepatier® 50mg/100mg | Tablets Requires MDT discussion with ID team |
| 06.04.01.01 | Elleste Duet® | Tablets Estradiol 1mg + norethisterone 1mg Estradiol 2mg + norethisterone 1mg |
| 06.04.01.01 | Elleste-Solo® | Tablets Estradiol 1mg Estradiol 2mg |
| 09.01.04 | Eltrombopag Revolade® | Tablets PbR Excluded - commissioned by CCG |
| 06.01.02.03 | Empagliflozin Jardiance® | Tablets |
| 05.03.01 | Emtricitabine Emtriva® | |
| 05.03.01 | Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera® | |
| 13.02.01.01 | Emulsiderm® Liquid Emulsion | |
| 13.02.01 | Emulsifying Ointment BP | Ointment |
| 02.05.05.01 | Enalapril | Tablets |
| 09.04 | Enfamil AR | Dose dependent on age |
| 09.04 | Enfamil olac | Dose dependent on age |
| 05.03.01 | Enfuvirtide Fuzeon® | |
| 02.08.01 | Enoxaparin | Subcutaneous injection Green2 or Green3 depending on indication. See GMMMG RAG list for full details |
| 02.01.02 | Enoximone Perfan® | Intravenous Injection |
| 09.04 | Enshake | Vanilla Chocolate Strawberry Banana |
| 09.04 | Ensure Compact 125ML | Vanilla Strawberry Banana |
| 09.04 | Ensure Plus Bottles 220ML | Chocolate Strawberry Coffee Vanilla Raspberry Banana Orange Fruits of Forest Neutral Peach |
| 09.04 | Ensure Plus Creme | Vanilla Neutral Chocolate Banana |
| 09.04 | Ensure Plus Fibre 200ML | Vanilla Chocolate Raspberry Banana Strawberry |
| 09.04 | Ensure Plus Juce 220ML | Strawberry Fruit Punch Lemon & Lime Orange Peach Apple |
| 09.04 | Ensure Plus Yoghurt Style 220ML | Strawberry Swirl Orchard Peach |
| 09.04 | Ensure Twocal 200ML | Banana vanilla Neutral Strawberry |
| 04.09.01 | Entacapone | |
| 05.03.03.01 | Entecavir Baraclude® | |
| 15.01.02 | Entonox® | |
| 13.02.01 | Epaderm® | Cream Ointment |
| 02.07.02 | Ephedrine | Intravenous injection |
| 12.02.02 | Ephedrine | Nasal drops Licensed for over 12 years of age only |
| 07.04.04 | Epirubicin | Bladder instillation Liaise with Pharmacy Aseptics for preparation of this product |
| 24.03 | Epirubicin IV Injection | |
| 02.02.03 | Eplerenone | Tablets |
| 09.01.03 | Epoetin alfa Eprex® | Injection |
| 09.01.03 | Epoetin beta NeoRecormon® | Injection |
| 02.08.01 | Epoprostenol Flolan® | Infusion |
| 02.09 | Eptifibatide Integrilin® | Injection Infusion |
| 09.06.04 | Ergocalciferol | Oral solution IM injection |
| 07.01.01 | Ergometrine Maleate | Injection |
| 07.01.01 | Ergometrine Maleate and Oxytocin Syntometrine® | Injection |
| 05.01.02.02 | Ertapenem | Intravenous Infusion Not for inpatient use |
| 01.02 | Erythromycin | Tablets Oral Suspension Intravenous infusion unlicensed indication |
| 05.01.05 | Erythromycin | Capsules Tablets Oral Suspension Intravenous Infusion |
| 11.03.01 | Erythromycin | Eye ointment unlicensed special |
| 13.06.02 | Erythromycin | Tablets First choice for rosacea. Alternative to oxytetracycline for acne. |
| 13.06.01 | Erythromycin 2% Stiemycin® | Topical solution |
| 13.06.01 | Erythromycin 40mg with Zinc Acetate 12mg/mL Zineryt® | Topical solution |
| 04.03.03 | Escitalopram | Tablets Oral drops |
| 02.04 | Esmolol | Intravenous Infusion Cardiologist/anaesthetist initiation only |
| 10.01.03 | Etanercept Enbrel® | Subcutaneous Injection |
| 10.01.03 | Etanercept Benepali® | Subcutaneous Injection
|
| 13.05.03 | Etanercept Enbrel® | |
| 05.01.09 | Ethambutol | Tablets |
| 02.13 | Ethanolamine Oleate | Injection |
| 08.03.01 | Ethinylestradiol | Tablets |
| 04.08.01 | Ethosuximide | Capsules Syrup |
| 10.01.01 | Etodolac | Capsules Modified release tablets |
| 15.01.01 | Etomidate Etomidate-Lipuro® | |
| 15.01.01 | Etomidate Hypnomidate® | |
| 07.03.02.02 | Etonorgestrel Nexplanon® | Implant |
| 24.03 | Etoposide IV Infusion | |
| 24.03 | Etoposide, Doxorubicin and Vincristine IV Infusion | |
| 10.01.01 | Etoricoxib Arcoxia® | Tablets |
| 05.03.01 | Etravirine Intelence® | |
| 02.12 | Evolocumab Repatha® | Pre-filled syringe Pre-filled pen Only as per NICE TA394. Requires completion of Blueteq form prior to initiation. Available via Homecare providers. |
| 06.04.01.01 | Evorel Conti® | Patches Estradiol 50micrograms/24hours + norethisterone 170micrograms/24hours |
| 06.04.01.01 | Evorel Sequi® | Patches Estradiol 50micrograms plus Estradiol 50micrograms + norethisterone acetate 170micrograms |
| 06.04.01.01 | Evorel® | Patches Estradiol 25, 50, 75, 100micrograms |
| 08.03.04.01 | Exemestane | Tablets |
| 06.01.02.03 | Exenatide Byetta® | Disposable pen |
| 06.01.02.03 | Exenatide Prolonged Release Bydureon® | Vial Once weekly preparation |
| 02.12 | Ezetimibe Ezetrol® | Tablets Not licensed for primary or secondary prevention of cardiovascular disease. |
| 10.01.04 | Febuxostat Adenuric® | Tablets |
| 06.04.01.01 | Femoston Conti® | Tablets Estradiol 1mg + dydrogesterone 5mg |
| 06.04.01.01 | Femoston® | Tablets Estradiol 1mg + dydrogesterone 10mg Estradiol 2mg + dydrogesterone 10mg |
| 02.12 | Fenofibrate | Capsules Tablets Fenofibrate has similar efficacy to bezafibrate in the reduction of triglycerides and is more potent in terms of LDL reduction and HDL elevation. |
| 04.07.02 | Fentanyl | Patches Buccal tablets (Effentora®) Palliative care only Nasal spray (PecFent®) Palliative care only |
| 15.01.04.03 | Fentanyl | |
| 09.01.01.02 | Ferric Carboxymaltose Ferinject® | Injection |
| 09.01.01.01 | Ferric Maltol Feraccru® | 30mg iron per capsule Consultant gastroenterologist only Alternative to IV iron in IBD patients intolerant to existing oral iron products, as per GMMMMG recommendations |
| 09.01.01.01 | Ferrous Fumarate | 45mg iron per 5ml |
| 09.01.01.01 | Ferrous Fumarate | 68mg iron per tablet |
| 09.01.01.01 | Ferrous Fumarate | 100mg iron per tablet |
| 09.01.01.01 | Ferrous Sulphate | 65mg iron per tablet |
| 07.04.02 | Fesoterodine | M/R Tablets |
| 03.04.01 | Fexofenadine | Tablets For established patients only |
| 05.01.07 | Fidaxomicin Dificlir® | Tablets Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 09.01.06 | Filgrastim Zarzio® | Injection |
| 06.04.02 | Finasteride | Tablets |
| 02.03.02 | Flecainide | Tablets Injection Specialist initiation only. Paediatric Use: Specialist initiation and secondary care management until stable. |
| 05.01.01.02 | Flucloxacillin | Capsules Oral Solution Injection |
| 24.01 | Flucloxacillin IV Syringe | 500mg/10mL 1000mg/20mL 2000mg/40mL |
| 05.02.01 | Fluconazole | Capsules Oral Suspension Intravenous Infusion |
| 07.02.02 | Fluconazole | Capsule |
| 12.03.02 | Fluconazole | Capsules |
| 05.02.05 | Flucytosine Ancotil® | Intravenous Infusion ID consultant initiation only |
| 24.01 | Flucytosine IV Infusion | |
| 24.03 | Fludarabine IV Infusion | |
| 06.03.01 | Fludrocortisone Acetate Florinef® | Tablets |
| 13.04 | Fludroxycortide Haelan® | Cream Ointment Tape (for chronic localised recalcitrant dermatoses, but not acute or weeping) |
| 12.01.01 | Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® | Ear drops |
| 12.01.01 | Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® | Ear drops |
| 13.04 | Fluocinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® | Cream |
| 13.04 | Fluocinolone Acetonide 0.00625% Synalar 1 in 4 Dilution® | Cream Ointment |
| 13.04 | Fluocinolone Acetonide 0.025% Synalar® | Cream Gel Ointment |
| 13.04 | Fluocinolone Acetonide 0.025% with Clioquinol 3% Synalar C® | Cream Ointment |
| 13.04 | Fluocinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N® | Cream Ointment |
| 11.04.01 | Fluocinolone intravitreal implant Iluvien® | Intravitreal implant Specialist use only |
| 13.04 | Fluocinonide 0.05% Metosyn® | FAPG cream Dermatology only |
| 11.08.02 | Fluorescein Sodium Minims® | Single-use eye drops Also available with local anaesthetic - see section 11.7 |
| 11.04.01 | Fluorometholone FML® | Eye drops Intra-ocular penetration is poor. It may be considered useful in a few patients with chronic low grade uveitis where raised intra-ocular pressure has been problematic. |
| 11.99.99.99 | Fluorouracil | Subconjunctival injection Prepared by pharmacy aseptics unit for named-patient use. |
| 13.08.01 | Fluorouracil 0.5%, Salicylic Acid 10% Actikerall® | Solution Dermatology only |
| 24.03 | Fluorouracil Ophthalmic | |
| 04.03.03 | Fluoxetine | Capsules Liquid |
| 04.02.01 | Flupentixol | Tablets |
| 04.03.04 | Flupentixol | |
| 04.02.02 | Flupentixol Decanoate Depixol® | |
| 04.02.02 | Fluphenazine Decanoate Modecate® | |
| 03.02 | Fluticasone | Metered dose inhaler (Flixotide® Evohaler) Dry powder inhaler (Flixotide® Accuhaler) Nebules |
| 03.02 | Fluticasone / umeclidinium / vilanterol Trelegy Ellipta® | Dry powder inhaler (DPI) Combination ICS/LABA/LAMA inhaler |
| 03.02 | Fluticasone and formoterol Flutiform® | Metered dose inhaler Combination ICS/LABA inhaler Licensed for ASTHMA only. |
| 03.02 | Fluticasone and salmeterol Seretide® | Metered dose inhaler (Seretide® Evohaler) Dry powder inhaler (Seretide® Accuhaler) Combination ICS/LABA inhaler Only the Seretide 500 Accuhaler is licensed for use in COPD. Seretide 250 Evohaler is very expensive - please consider alternatives where possible. Not to be initiated, but can be continued in established patients. |
| 03.02 | Fluticasone furoate & vilanterol Relvar Ellipta® | Dry powder inhaler Combination ICS/LABA inhaler 184/22 strength licensed for ASTHMA only |
| 12.02.01 | Fluticasone Propionate | 50mcg/metered dose Nasal Spray |
| 04.03.03 | Fluvoxamine Maleate | Tablets |
| 09.01.02 | Folic Acid | Tablets Oral syrup Injection (unlicensed) |
| 02.08.01 | Fondaparinux Arixtra® | Subcutaneous injection
Awaiting Trust-approved protocols for other indications. |
| 09.06.07 | Forceval® | Capsules Soluble Tablets |
| 03.01.01.01 | Formoterol | Dry powder inhaler 12 micrograms/dose (Easyhaler®) Dry powder inhaler 6 micrograms/dose, 12 micrograms/dose (Oxis® Turbohaler) |
| 05.03.01 | Fosamprenavir Telzir® | |
| 24.03 | Foscarnet IV Infusion | |
| 05.03.02.02 | Foscarnet Sodium Foscavir® | |
| 05.01.13 | Fosfomycin | Granules for oral suspension Injection Injection - Microbiology / ID recommendation only; for the treatment of carbapenemase-producing enterobacteriaceae |
| 08.03.04.01 | Fulvestrant Faslodex® | Intramuscular injection
|
| 02.02.02 | Furosemide | Tablets Liquid Injection |
| 11.03.01 | Fusidic Acid | Eye drops |
| 13.10.01.02 | Fusidic Acid 2% Fucidin® | Cream Ointment |
| 04.07.03 | Gabapentin | Capsules Oral solution |
| 04.07.03 | Gabapentin | Capsules Oral solution |
| 04.08.01 | Gabapentin | Capsules Oral solution |
| 06.01.05 | Gabapentin | Capsules Oral solution |
| 04.11 | Galantamine | Tablets M/R capsules Oral solution Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
| 05.03.02.02 | Ganciclovir Cymevene® | Prepared by pharmacy aseptics during working hours. Liaise with pharmacy. |
| 11.03.03 | Ganciclovir | Eye gel Specialist ophthalmologist only |
| 24.03 | Ganciclovir IV Infusion | |
| 24.03 | Ganciclovir IV Infusion | |
| 01.01.02 | Gaviscon Advance | Suspension Chewable tablets |
| 01.01.02 | Gaviscon Infant | Oral powder |
| 09.02.02.02 | Gelatin Gelofusine® | May be supplied as an alternative to Gelaspan if unavailable |
| 09.02.02.02 | Gelatin Gelaspan® | |
| 12.03.01 | Gelclair® | Sachets |
| 24.03 | Gemcitabine IV Infusion | |
| 07.01.01 | Gemeprost | Pessaries |
| 24.03 | Gemtuzumab IV Infusion | |
| 05.01.04 | Gentamicin | Injection |
| 11.03.01 | Gentamicin Genticin® | 0.3% eye/ear drops 1.5% eye drops unlicensed special |
| 12.01.01 | Gentamicin Genticin® | Ear/eye drops Not on GMMMG formulary |
| 12.03.05 | Glandosane® | Aerosol spray |
| 06.01.02.01 | Gliclazide | Tablets |
| 06.01.02.01 | Glimepiride | Tablets |
| 06.01.02.01 | Glipizide | Tablets |
| 06.01.04 | Glucagon GlucaGen® HypoKit | |
| 06.01.04 | GlucoGel® | |
| 09.02.02.01 | Glucose 10% Intravenous | 500ml bag 1L bag |
| 09.02.02.01 | Glucose 15% Intravenous | 500ml bag |
| 09.02.02.01 | Glucose 20% Intravenous | 500ml bag |
| 09.02.02.01 | Glucose 5% Intravenous | 50ml bag 100ml bag 250ml bag 500ml bag 500ml Polyfusor 1L bag |
| 09.02.02.01 | Glucose 50% Intravenous | 20ml amps 50ml vial 500ml bag |
| 01.06.02 | Glycerol (Glycerin) | Suppositories (1st line for rectal use) |
| 02.06.01 | Glyceryl Trinitrate | Spray Sublingual Tablets Patches Injection |
| 01.07.04 | Glyceryl Trinitrate 0.4% Ointment Rectogesic® | |
| 07.04.04 | Glycine 1.5% | Bladder irrigation solution |
| 03.01.02 | Glycopyrronium Seebri breezhaler® | Inhalation powder, hard capsule for use with Breezhaler® device Reserved for COPD patients with intolerance to tiotropium, or those who cannot use tiotropium devices. |
| 15.01.03 | Glycopyrronium | |
| 03.01.04 | Glycopyrronium / Indacaterol Ultibro® Breezhaler | Combination LABA/LAMA inhaler |
| 13.12 | Glycopyrronium bromide | Dermatology only |
| 10.01.03 | Golimumab | Subcutaneous Injection |
| 06.07.02 | Goserelin | Intradermal implant 3.6mg (every 28 days) For use in breast and prostate cancer, see sections 8.3.4.1 and 8.3.4.2. "Amber" for licensed indications, "Red" for all unlicensed uses. |
| 08.03.04.02 | Goserelin Zoladex® | Zoladex® implant Zoladex®LA implant  For licensed indications |
| 02.05.03 | Guanethidine Monosulphate Ismelin® | Intramuscular injection Licensed for rapid control of blood pressure, however alternative agents are preferred (BNF). |
| 04.04 | Guanfacine Intuniv® | Prolonged-release tablets |
| 14.04 | Haemophilus influenzae type B Combined Vaccine Menitorix® | |
| 04.02.01 | Haloperidol | Tablets Capsules Oral liquid Injection |
| 04.02.02 | Haloperidol Haldol Decanoate® | |
| 04.06 | Haloperidol | Tablets Capsules Oral liquid Injection |
| 02.08.01 | Heparin | Flush solution For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes. The role of heparin flushes in maintaining patency of arterial and central venous catheters is unclear (BNF). All flush solutions must be prescribed. See NPSA Rapid Response Alert. |
| 02.08.01 | Heparin | Injection |
| 24.01 | Heparin 50 units in 50mL 0.18% sodium chloride | |
| 13.13 | Heparinoid 0.3% Hirudoid® | Cream |
| 14.04 | Hepatitis A vaccine Single Component Havrix® | |
| 14.04 | Hepatitis A vaccine with Hepatitis B vaccine Twinrix® | |
| 14.04 | Hepatitis A vaccine with typhoid vaccine Hepatyrix® | |
| 14.04 | Hepatitis A vaccine with typhoid vaccine VIATIM® | |
| 14.05.02 | Hepatitis B immunoglobulin | Medical team to contact Clinical Virology at Central Manchester Foundation Trust (0161 276 8853) |
| 14.04 | Hepatitis B vaccine Single Component Engerix B® | |
| 14.04 | Hepatitis B vaccine Single Component Fendrix® | Approved by Medical D&T on 26/3/15 for use after failure of previous vaccination course, as per BHIVA guidelines. |
| 14.04 | Hepatitis B vaccine Single Component HBvaxPRO® | |
| 13.11.02 | Hibiscrub® Chlorhexidine | |
| 13.11.02 | Hibitane Obstetric® | Cream |
| 06.01.01.01 | Humalog® Insulin Lispro | 3ml cartridge (via Autopen® Classic or HumaPen®) 3ml prefilled disposable pen (Kwikpen®) |
| 06.01.01.02 | Humalog® Mix25 Biphasic Insulin Lispro | 3ml cartridge (via Humapen® Luxura device) 3ml prefilled disposable pen (Kwikpen® ) |
| 06.01.01.02 | Humalog® Mix50 Biphasic Insulin Lispro | 3ml cartridge (via Humapen® Luxura device) 3ml disposable prefilled pen (Kwikpen®) |
| 09.02.02.02 | Human Albumin Solution | This is a BLOOD product. Obtain from haematology (not pharmacy). |
| 06.05.01 | Human Menopausal Gonadotrophins Menopur® | Injection |
| 14.04 | Human papilloma virus vaccine Gardasil® | |
| 06.01.01.02 | Humulin® I Isophane Insulin | 3ml cartridge (via Humapen® Luxura device) 3ml prefilled disposable pen (Kwikpen®) |
| 06.01.01.02 | Humulin® M3 Biphasic Isophane Insulin | 3ml cartridge (via Humapen® Luxura device) 3ml prefilled disposable pen (Kwikpen®) |
| 06.01.01.01 | Humulin® S | 3ml cartridge 10ml vial |
| 10.01 | Hyaluronic acid | See link |
| 10.03.01 | Hyaluronidase | Injection |
| 02.05.01 | Hydralazine | Tablets Injection Oral hydralazine may be used in combination with long-acting nitrates in patients with heart failure who are still symptomatic despite optimal therapy with ACE inhibitor and beta blocker or when ACE inhibitors and ARBs are contra-indicated or not tolerated. Not to be used as monotherapy (causes tachycardia and fluid retention). (BNF) |
| 01.05.02 | Hydrocortisone | Rectal foam Injection |
| 06.03.02 | Hydrocortisone | Tablets Injection (as sodium phosphate) Injection (as sodium succinate) |
| 12.03.01 | Hydrocortisone Corlan® | Oromucosal tablets |
| 13.04 | Hydrocortisone | Cream (0.5%, 1%, 2.5%) Ointment (0.5%, 1%, 2.5%) |
| 13.04 | Hydrocortisone 0.5% with Nystatin and Chlorhexidine Nystaform-HC® | Cream Ointment |
| 13.04 | Hydrocortisone 0.5% with Nystatin, Benzalkonium and Dimeticone Timodine® | Cream |
| 13.04 | Hydrocortisone 1% with Clotrimazole 1% Canesten HC® | Cream |
| 13.04 | Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® | Cream Ointment |
| 13.04 | Hydrocortisone 1%, Urea 10% and Lactic Acid 5% Calmurid HC® | Cream |
| 10.01.02.02 | Hydrocortisone acetate Hydrocortistab® | 25mg/ml intra-articular injection |
| 13.04 | Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® | Cream |
| 12.01.01 | Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC | Ear drops |
| 13.04 | Hydrocortisone Butyrate 0.1% Locoid® | Cream Ointment |
| 12.01.01 | Hydrocortisone with Antibactrial Otosporin® | Ear drops |
| 12.03.04 | Hydrogen Peroxide | Mouthwash |
| 13.11.06 | Hydrogen Peroxide Solution BP | |
| 13.02.01.01 | Hydromol® bath and shower emollient | |
| 13.02.01 | Hydromol® ointment | Ointment |
| 09.01.02 | Hydroxocobalamin | Injection |
| 08.01.05 | Hydroxycarbamide Hydrea® |
|
| 10.01.03 | Hydroxychloroquine | Tablets |
| 03.04.01 | Hydroxyzine | Tablets Oral Solution Hydroxyzine is favoured by dermatologists for its anti-itch and sedating effects. |
| 10.01 | Hylan G-F 20 Synvisc® | See link |
| 01.02 | Hyoscine Butylbromide Buscopan® | Tablets Injection |
| 04.06 | Hyoscine Hydrobromide | Tablets Patches |
| 04.06 | Hyoscine Hydrobromide | Tablets Patch |
| 15.01.03 | Hyoscine Hydrobromide | |
| 03.07 | Hypertonic sodium chloride | Nebuliser solution |
| 11.08.01 | Hypromellose | 0.3% eye drops 0.5% eye drops |
| 06.01.01.02 | Hypurin® Bovine Isophane Isophane Insulin | 3ml cartridges (via Autopen® Classic) • Some long-standing type 1 diabetic patients may be on animal insulin. • Patients need not be transferred to human insulin unless clinical need dictates • Human insulin and analogues should be used in preference to animal insulin |
| 06.01.01.01 | Hypurin® Bovine Neutral | 3ml cartridge (for Autopen® Classic) • Some long-standing type 1 diabetic patients may be on animal insulin. • Patients need not be transferred to human insulin unless clinical need dictates • Human insulin and analogues should be used in preference to animal insulin |
| 06.01.01.02 | Hypurin® Porcine 30/70 Mix Biphasic Isophane Insulin | 3ml cartridge (for Autopen® Classic) • Some long-standing type 1 diabetic patients may be on animal insulin. • Patients need not be transferred to human insulin unless clinical need dictates • Human insulin and analogues should be used in preference to animal insulin |
| 06.01.01.02 | Hypurin® Porcine Isophane Isophane Insulin | 3ml cartridge (via Autopen® Classic) • Some long-standing type 1 diabetic patients may be on animal insulin. • Patients need not be transferred to human insulin unless clinical need dictates • Human insulin and analogues should be used in preference to animal insulin |
| 06.01.01.01 | Hypurin® Porcine Neutral | 3ml cartridge (for Autopen® Classic) • Some long-standing type 1 diabetic patients may be on animal insulin. • Patients need not be transferred to human insulin unless clinical need dictates • Human insulin and analogues should be used in preference to animal insulin |
| 06.01.01.02 | Hypurin®Bovine Lente Insulin Zinc suspension | 10ml vial • Some long-standing type 1 diabetic patients may be on animal insulin. • Patients need not be transferred to human insulin unless clinical need dictates • Human insulin and analogues should be used in preference to animal insulin |
| 06.06.02 | Ibandronic Acid Bondronat® | 50mg Tablets Concentrate for infusion Approved for reduction of bone damage in bone metastases in advanced breast cancer |
| 07.01.01.01 | Ibuprofen Pedea® | Intravenous solution |
| 10.01.01 | Ibuprofen | Tablets Oral suspension 5% gel |
| 10.03.02 | Ibuprofen gel | Gel |
| 24.03 | Idarubicin IV Infusion | |
| 24.03 | Ifosfamide and Mesna IV Infusion | |
| 02.05.01 | Iloprost | Injectionunlicensed For use in rheumatology patients, see attached guidelines. |
| 04.03.01 | Imipramine | Tablets Oral solution |
| 04.07.03 | Imipramine | Tablets Oral solution |
| 07.04.02 | Imipramine | Tablets Oral solution |
| 13.07 | Imiquimod Aldara® | 5% Cream |
| 14.04 | Inactivated Influenza Vaccine (Split Virion) | |
| 03.01.01.01 | Indacaterol | Dry powder inhaler 150 microgram/dose, 300 microgram/dose (Onbrez Breezhaler®) May be considered as a treatment option for COPD patients in whom another long acting β-adrenoceptor agonist (LABA) would be suitable (GMMMG). Not licensed for asthma. |
| 02.02.01 | Indapamide | Tablets First choice for hypertension, where a thiazide is indicated (see NICE CG127: Hypertension). N.B. Modified release tablets are NON-formulary |
| 07.01.01.01 | Indometacin | Injection |
| 07.01.03 | Indometacin | Suppositories Capsules Unlicensed indication |
| 10.01.01 | Indometacin | Capsules Modified-release capsules Suppositories |
| 13.11.01 | Industrial Methylated Spirit BP | |
| 09.04 | Infatrini Peptisorb | Dose dependent on age |
| 01.05.03 | Infliximab Remsima® | For new patients only |
| 01.05.03 | Infliximab Remicade® | |
| 10.01.03 | Infliximab | Intravenous Infusion |
| 13.05.03 | Infliximab Remicade® | |
| 24.03 | Infliximab IV Infusion Remsima | Outsourced product - not prepared by PAT Aseptic Services |
| 24.03 | Infliximab IV Infusion Inflectra | |
| 24.03 | Infliximab IV Infusion Remicade | |
| 13.08.01 | Ingenol mebutate Picato® | Gel Dermatology Only |
| 06.01.01.02 | Insulatard® Isophane Insulin | 3ml cartridge (via Novopen®4) 3ml prefilled disposable pen (Innolet®) |
| 06.01.01.02 | Insuman® Basal Isophane Insulin | 3ml cartridge (via ClikSTAR® or Autopen®24 devices) 3ml prefilled disposable pen (Solostar®) |
| 06.01.01.02 | Insuman® Comb 15 Biphasic Isophane Insulin | 3ml cartridge (via ClikSTAR® or Autopen®24 devices) |
| 06.01.01.02 | Insuman® Comb 25 Biphasic Isophane Insulin | 3ml cartridge (via ClikSTAR® or Autopen®24 devices) 3ml prefilled disposable pen (Solostar®) |
| 06.01.01.02 | Insuman® Comb 50 Biphasic Isophane Insulin | 3ml cartridge (via ClikSTAR® or Autopen®24 devices) |
| 06.01.01.01 | Insuman® Rapid | 3ml cartridge (via ClikSTAR® or Autopen® 24) |
| 08.02.04 | Interferon Alfa-2b IntronA® | |
| 08.02.04 | Interferon Alfa-2b Roferon-A® | |
| 07.03.04 | Intra-uterine Contraceptive Devices TT 380 Slimline® | |
| 07.03.02.03 | Intra-uterine Progestogen Only System Mirena® | |
| 03.01.02 | Ipratropium | Metered dose inhaler (MDI) 20 micrograms/dose Nebuliser solution 250 micrograms/ml, 500 micrograms/ml |
| 12.02.02 | Ipratropium Bromide Rinatec® | |
| 02.05.05.02 | Irbesartan | Tablets GMMMG endorse use for renal patients. |
| 09.01.01.02 | Iron Dextran CosmoFer® | Injection |
| 09.01.01.02 | Iron Isomaltoside Monofer® | Injection |
| 09.01.01.02 | Iron Sucrose Venofer® | Injection |
| 15.01.02 | Isoflurane | |
| 05.01.09 | Isoniazid | Tablets Injection |
| 02.07.01 | Isoprenaline | Concentrate for injection or infusion (dilute before use). unlicensed |
| 02.06.01 | Isosorbide Dinitrate | Injection |
| 02.06.01 | Isosorbide Mononitrate | Modified release tablets Tablets |
| 13.06.02 | Isotretinoin Roaccutane® | Capsules Dermatology only |
| 01.06.01 | Ispaghula Husk | Granules |
| 05.02.01 | Itraconazole | Capsules Oral Liquid Intravenous Infusion Itraconazole is associated with liver damage and should no be given to patients with a history of liver disease. Following reports of heart failure, caution is advised when prescribing itraconazole to patients at high risk of heart failure (BNF). |
| 02.06.03 | Ivabradine | Tablets Specialist initiation Ivabradine should only be initiated in people with NYHA class II to IV stable chronic heart failure with systolic dysfunction who: |
| 05.05.06 | Ivermectin | Tabletsunlicensed |
| 05.05.07 | Ivermectin | Tabletsunlicensed |
| 05.05.08 | Ivermectin | Tabletsunlicensed |
| 13.10.04 | Ivermectin | Tabletsunlicensed |
| 14.04 | Japanese Encephalitis Vaccine Ixiaro® | NMGH Travel Clinic only |
| 09.04.02 | Jevity | 500ml 1000ml 1500ml |
| 09.04.02 | Jevity 1.5kcal | 500ml 1000ml 1500ml |
| 09.04.02 | Jevity PLUS | 500ml 1000ml 1500ml |
| 09.04.02 | Jevity PLUS HP | |
| 09.04.02 | Jevity Promote | |
| 04.07.03 | Ketamine oral solution | Specialist initiation by pain team or palliative care only Unlicensed |
| 07.02.02 | Ketoconazole 2% | Cream |
| 13.10.02 | Ketoconazole 2% Cream Nizoral® | Cream |
| 13.09 | Ketoconazole 2% Shampoo | Shampoo |
| 10.03.02 | Ketoprofen gel | Gel |
| 11.08.02 | Ketorolac Acular® | Eye drops Ophthalmic specialist initiation only |
| 15.01.04.02 | Ketorolac Toradol® | |
| 09.06.07 | Ketovite® | Tablets Liquid |
| 01.06.05 | Klean-Prep® | |
| 06.04.01.01 | Kliofem® | Tablets Estradiol 2mg + norethisterone acetate 1mg |
| 06.04.01.01 | Kliovance® | Tablets Estradiol 1mg + norethisterone acetate 500micrograms |
| 02.04 | Labetalol | Tablets Injection Infusion Labetalol is a first line option for the management of hypertension in pregnancy (see NICE Guidance - Hypertension in Pregnancy). |
| 04.08.01 | Lacosamide | Tablets Syrup |
| 01.06.04 | Lactulose Solution | Lactulose takes up to 48 hours to work but is often inappropriately used “when required”. It is unpleasant to take and compliance may be a problem. Its main clinical benefit is in the management of hepatic encephalopathy. |
| 05.03.01 | Lamivudine | Tablets Oral Solution |
| 05.03.03.01 | Lamivudine | Tablets Oral Solution |
| 04.08.01 | Lamotrigine | Tablets Dispersible tablets |
| 08.03.04.03 | Lanreotide Somatuline® | Injection (Somatuline® LA and Somatuline® Autogel)
|
| 01.03.05 | Lansoprazole | Capsules Orodispersible tablets - first choice for patients with enteral feeding tubes |
| 09.05.02.02 | Lanthanum Fosrenol ® | Tablets |
| 06.01.01.02 | Lantus® Insulin Glargine | 3ml cartridge (via ClikSTAR® or Autopen®24 devices) 3ml prefilled disposable pen (Solostar®) |
| 11.06 | Latanoprost | Eye drops Single-use eye drops |
| 11.06 | Latanoprost 0.005% with Timolol 0.5% | Eye drops Combination products are licensed for once daily use where prostaglandin analogue alone is not adequate. Only use where patient has difficulty with compliance/administration. |
| 05.03.03.02 | Ledipasvir/Sofosbuvir Harvoni® 90mg/400mg | Tablets Requires MDT discussion with ID team |
| 10.01.03 | Leflunomide | Tablets Specialist Initiation Only |
| 08.02.04 | Lenalidomide Revlimid® | Capsules |
| 09.01.06 | Lenograstim Granocyte® | Injection |
| 02.06.02 | Lercanidipine | Tablets |
| 08.03.04.01 | Letrozole | Tablets |
| 06.07.02 | Leuprorelin Prostap® | Prefilled dual chamber syringe 3.75mg (monthly) 11.25mg (every 3 months) For use in prostate cancer, see section 8.3.4.2."Amber" for licensed indications, "Red" for all unlicensed uses. |
| 08.03.04.02 | Leuprorelin Acetate Prostap® | Prostap®3 DCS 11.25mg injection Prostap® SR DCS 3.75mg injection 1st choice for prostate cancer
|
| 05.05.02 | LEVAMISOLE Tablets 50 mg | Tabletsunlicensed |
| 06.01.01.02 | Levemir® Insulin Detemir | 3ml cartridges (via Novopen®4 device) 3ml prefilled disposable pen (Flexpen® or Innolet®) |
| 04.08.01 | Levetiracetam Keppra® | Tablets Oral solution Intravenous infusion |
| 11.06 | Levobunolol | Eye drops Unit dose eye drops |
| 15.02 | Levobupivacaine Chirocaine® | |
| 05.01.12 | Levofloxacin | Tablets Intravenous Infusion |
| 11.03.01 | Levofloxacin | Eye drops Unit dose eye drops |
| 13.03 | Levomenthol Dermacool® | Cream |
| 04.02.01 | Levomepromazine | Tablets Injection |
| 04.06 | Levomepromazine | Tablets Injection In the last days of life, levomepromazine is used as a first-line antiemetic. |
| 04.06 | Levomepromazine | Tablets Injection |
| 07.03.05 | Levonorgestrel Levonelle® 1500 | |
| 06.02.01 | Levothyroxine | Tablets Oral liquid |
| 12.03.01 | Lidocaine | 10% mouth spray 5% ointment |
| 15.02 | Lidocaine | |
| 01.07.01 | Lidocaine 5% | Ointment |
| 11.07 | Lidocaine Hydrochloride 4% with Fluorescein 0.25% Minims® | Single-use eye drops |
| 01.06.07 | Linaclotide Constella® | Capsules Gastroenterologists only |
| 06.01.02.03 | Linagliptin Trajenta® | Tablets First choice 'Gliptin' for patients with moderate or severe renal impairment (CrCl<50ml/min, eGFR<59ml/min) |
| 05.01.07 | Linezolid | Tablets Suspension Intravenous Infusion Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 06.02.01 | Liothyronine | Tablets
Injection
|
| 13.02.01 | Lipobase® | Cream Dermatology only |
| 13.02.01 | Liquid and White Soft Paraffin Ointment (50:50) | Ointment |
| 11.08.01 | Liquid Paraffin Lacri-Lube® | Eye ointment |
| 06.01.02.03 | Liraglutide Victoza® | Disposable pen |
| 04.04 | Lisdexamfetamine Elvanse® | Capsules Pennine Care: Use may be considered second or third line when treatment with methylphenidate m/r not successful and patient has swallowing difficulties (as atomoxetine caps cannot be opened) and where drug diversion is not a risk. |
| 02.05.05.01 | Lisinopril | Tablets |
| 04.02.03 | Lithium Carbonate tablets Camcolit® or Priadel® | |
| 04.02.03 | Lithium Citrate liquid Li-Liquid® or Priadel® | |
| 06.01.02.03 | Lixisenatide Lyxumia® | Disposable pen |
| 11.04.02 | Lodoxamide Alomide® | Eye drops |
| 07.03.01 | Loestrin 20® Ethinylestradiol 20 mcg / norethisterone 1mg | Low strength preparation |
| 04.03.01 | Lofepramine | Tablets Oral suspension |
| 04.10.03 | Lofexidine Hydrochloride | Specialist initiation only |
| 07.03.01 | Logynon® Ethinylestradiol / levonorgestrel phased pill | Tri-phasic preparation |
| 01.04.02 | Loperamide | Capsules Syrup |
| 05.03.01 | Lopinavir and Ritonavir Kaletra® | |
| 03.04.01 | Loratadine | Tablets Oral Solution |
| 04.01.02 | Lorazepam | Tablets Injection |
| 15.01.04.01 | Lorazepam | |
| 04.08.02 | Lorazepam Injection | |
| 02.05.05.02 | Losartan | Tablets |
| 05.01.03 | Lymecycline | Capsules |
| 13.06.02 | Lymecycline | Capsules To be initiated by Dermatology only Alternative choice for acne only |
| 01.06.04 | Macrogol Movicol® sachet | |
| 09.05.01.03 | Magnesium Aspartate Magnaspartate® | Sachets |
| 09.05.01.03 | Magnesium Sulphate | 50% Injection 10% Injection 1 gram Mg = 4 mmol Mg. |
| 13.10.05 | Magnesium Sulphate Paste BP | Paste |
| 01.01.01 | Magnesium Trisilicate Mixture BP | |
| 13.10.04 | Malathion 0.5% Derbac-M® | Liquid |
| 13.10.04 | Malathion 0.5% Derbac-M® | Liquid |
| 02.02.05 | Mannitol | Intravenous Infusion |
| 05.03.01 | Maraviroc | |
| 14.04 | Measles, Mumps and Rubella Vaccine, Live (MMR) | |
| 05.05.01 | Mebendazole | Chewable tablets Oral suspension |
| 05.05.04 | Mebendazole | See section 5.5.1 |
| 01.02 | Mebeverine Hydrochloride | Tablets Oral suspension |
| 06.04.01.02 | Medroxyprogesterone Acetate | Tablets |
| 07.03.02.02 | Medroxyprogesterone Acetate Depo-Provera® | 12-weekly IM injection |
| 08.03.02 | Medroxyprogesterone Acetate Provera® | Tablets |
| 10.01.01 | Mefenamic Acid | Capsules Tablets Oral suspension |
| 05.04.01 | Mefloquine | Tablets |
| 08.03.02 | Megestrol Acetate Megace® | Tablets |
| 04.01.01 | Melatonin | M/R tabletsCapsules (unlicensed) Tablets (unlicensed) Oral liquid (unlicensed)
The licensed M/R tablets can be crushed for administration in dysphagia or via enteral feeding tubes if necessary. This obviously means that they would no longer be 'modified release'. |
| 10.01.01 | Meloxicam | Tablets |
| 04.11 | Memantine | Tablets Oral solution Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
| 09.06.06 | Menadiol Sodium Phosphate | Tablets Water-soluble. For use in patients with fat malabsorption syndromes, e.g. biliary obstruction or hepatic disease (BNF) |
| 14.04 | Meningococcal group B Vaccine Bexsero® | |
| 14.04 | Meningococcal group C conjugate vaccine NeisVac-C® | |
| 14.04 | Meningococcal polysaccharide A, C, W135 and Y vaccine Nimenrix® or Menveo® | |
| 01.05.03 | Mercaptopurine | Tablets |
| 05.01.02.02 | Meropenem | Injection Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 01.05.01 | Mesalazine Mezavant® XL | Tablets Specialist initiation only For when symptoms are not controlled with 400mg or 800mg preparations or when concordance is an issue. |
| 01.05.01 | Mesalazine Asacol® | Tablets Foam enema Suppositories |
| 01.05.01 | Mesalazine Pentasa® | Tablets Granules Retention enema Suppositories Tablets may be dispersed in water for patients with dysphagia / enteral feeding tubes |
| 01.05.01 | Mesalazine Salofalk® | Granules Granules may be used for patients with swallowing difficulties. Tablets are NON FORMULARY |
| 01.05.01 | Mesalazine Octasa® | Tablets |
| 08.01 | Mesna | Tablets Injection |
| 24.01 | Mesna IV Infusion | |
| 13.02.02 | Metanium® | Ointment |
| 02.07.02 | Metaraminol | Injectionunlicensed |
| 06.01.02.02 | Metformin | Tablets Oral Solution
|
| 06.01.02.02 | Metformin Hydrochloride Modified Release | MR Tablets Metformin MR should only be used where the standard metformin tablets have been tried and are not tolerated due to GI problems. Any new prescription of the MR preparation should be reviewed soon after initiation (recommend checking HbA1c after 3 months and assess patient for adherence to treatment/adverse effects), discontinue if not tolerated or ineffective. |
| 04.10.03 | Methadone | Solution Injection |
| 03.09.01 | Methadone Hydrochloride Methadone® Linctus | Oral solution Methadone has been used to control distressing cough in terminal lung cancer, although morphine is now preferred. In other circumstances, it is contraindicated because it induces sputum retention and ventilatory failure. Also causes opioid dependence, has a long duration of action, and tends to accumulate. (BNF 67) |
| 10.01.03 | Methotrexate | Tablets Pre-filled injection pen (supplied to patients via homecare arrangements) Specialist initiation onlyWEEKLY dosing |
| 13.05.03 | Methotrexate | Tablets Injection |
| 01.05.03 | Methotrexate - injection | |
| 01.05.03 | Methotrexate - oral | Tablets |
| 24.03 | Methotrexate IM Injection | |
| 24.03 | Methotrexate Intrathecal Injection | |
| 24.03 | Methotrexate IV Infusion | |
| 13.05.02 | Methoxypsoralen | Tablets Dermatology only |
| 01.06.01 | Methycellulose Celevac® | Tablets |
| 13.08.01 | Methyl-5-Aminolevulinate Metvix® | Cream Dermatology Only |
| 02.05.02 | Methyldopa | Tablets Used in the management of hypertension in pregnancy |
| 04.04 | Methylphenidate | Tablets M/R tablets or capsules First choice brand for Pennine Care is Matoride XL. |
| 06.03.02 | Methylprednisolone | Injection Depot injection Tablets |
| 10.01.02.02 | Methylprednisolone Acetate Depo-Medrone® | Injection |
| 10.01.02.02 | Methylprednisolone Acetate Depo-Medrone® with Lidocaine | Injection |
| 01.02 | Metoclopramide | Tablets Oral solution Injection Should only be prescribed for short-term use (up to 5 days). For adults, the maximum dose in 24 hours is 30mg. |
| 04.06 | Metoclopramide | Tablets Oral solution Injection |
| 04.06 | Metoclopramide | Tablets Oral solution Injection |
| 04.06 | Metoclopramide | Tablets Suspension Injection |
| 02.02.01 | Metolazone | Tabletsunlicensed UK licensed product discontinued in 2012. Unlicensed import product is available from Pharmacy. |
| 02.04 | Metoprolol | Tablets (not a preferred GMMMG option) Injection |
| 05.01.11 | Metronidazole | Tablets Oral suspension Suppositories Intravenous Infusion |
| 05.04.02 | Metronidazole | See section 5.1.11 |
| 07.02.02 | Metronidazole | Vaginal gel |
| 13.10.01.02 | Metronidazole gel | Gel |
| 06.07.03 | Metyrapone Metopirone® | Capsules For specialist use only |
| 04.03.01 | Mianserin | |
| 07.02.02 | Miconazole | Cream |
| 12.03.02 | Miconazole Daktarin® | Oral Gel |
| 13.10.02 | Miconazole 2% Cream | Cream |
| 07.03.01 | Microgynon 30 ED® Ethinylestradiol 30 mcg / levonorgestrel 150 mcg | Standard strength, everyday preparation |
| 07.03.01 | Microgynon 30® or Levest® Ethinylestradiol 30mcg / levonorgestrel 150mcg | Standard strength preparation |
| 07.03.02 | Micronor® Norethisterone 350mcg | |
| 15.01.04.01 | Midazolam Hypnovel® | |
| 04.08.02 | Midazolam Buccal Solution Buccolam® | Paediatric use only |
| 02.07 | Midodrine | Tablets For hypotensive states. Not to be initiated in primary care. |
| 07.01.02 | Mifepristone Mifegyne® | Tablets |
| 04.07.04.01 | Migraleve® | "Pink" tablets (buclizine 6.25mg, paracetamol 500mg, codeine phosphate 8mg) "Yellow" tablets (paracetamol 500mg, codeine phosphate 8mg) |
| 07.04.02 | Mirabegron | M/R tablets Only recommended if antimuscarinic drugs are contraindicated, clinically ineffective or have unacceptable side effects. |
| 04.03.04 | Mirtazapine | Tablets Orodispersible tablets |
| 07.01.01 | Misoprostol | Tablets (for oral or vaginal administration)Unlicensed indication |
| 07.04.04 | Mitomycin | Bladder instillation |
| 11.99.99.99 | Mitomycin C | Subconjunctival injection Prepared by pharmacy aseptics unit on named-patient basis |
| 24.03 | Mitoxantrone IV Infusion | |
| 15.01.05 | Mivacurium Chloride Mivacron® | |
| 04.03.02 | Moclobemide | |
| 04.04 | Modafinil | Tablets AMBER for sleepiness associated with narcolepsy |
| 12.02.01 | Mometasone Furoate Nasonex® | Nasal Spray |
| 13.04 | Mometasone Furoate 0.1% Non-proprietary or Elocon® | Cream Ointment Dermatology only |
| 03.03.02 | Montelukast Singulair® | Tablets Chewable Tablets Granules The Scottish Medicines Compendium has advised (June 2007) that montelukast chewable tablet and granules are restricted for use as an alternative treatment option to low-dose inhaled corticosteroids for children 2 to 14 years of age with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids. The chewable tablets and granules should be initiated by specialists in paediatric asthma care. |
| 04.07.02 | Morphine | Oral solution:unlicensed) Concentrated oral solution: Tablets M/R 12-hourly oral preparations: M/R 24-hourly oral preparations: Suppositories Injection PCA syringe ( unlicensed) |
| 01.06.05 | Moviprep® | |
| 05.01.12 | Moxifloxacin | Tablets Intravenous Infusion Can only be prescribed following discussion with Microbiology or an ID physician |
| 02.05.02 | Moxonidine | Tablets Specialist initiation only Moxonidine is considered a last-line management option for resistant hypertension. |
| 09.06.07 | Multivitamin preparations Abidec® | Oral drops |
| 09.06.07 | Multivitamin preparations Dalivit® | Oral drops Only use if Abidec is unavailable |
| 13.10.01.01 | Mupirocin Bactroban® | See 12.02.03 |
| 12.02.03 | Mupirocin 2% in White Soft Paraffin Bactroban Nasal® | Nasal ointment For MRSA eradication only |
| 09.06.07 | Mutivitamins | Capsules |
| 10.01.03 | Mycophenolate | Tablets Capsules unlicensed indication (rheumatoid arthritis). |
| 08.02.01 | Mycophenolate Mofetil | Capsules Tablets Oral suspension All new patients commenced on mycophenolate mofetil should be commenced on a "branded generic" preparation. |
| 13.05.03 | Mycophenolate mofetil | Tablets Capsules Oral suspension unlicensed indication (severe refractory eczema) |
| 08.02.01 | Mycophenolic Acid Myfortic® | Gastro-resistant tablets Mycophenolate and mycophenolic acid are not interchangeable. Patients on Myfortic® must remain on Myfortic®. |
| 08.02.01 | Mycophenolic Acid Myfortic® | Gastro-resistant tablets Mycophenolate and mycophenolic acid are not interchangeable. Patients on Myfortic® must remain on Myfortic®. |
| 24.03 | Mytomycin Ophthalmic | |
| 10.01.01 | Nabumetone | Tablets Oral suspension |
| 02.06.04 | Naftidrofuryl Oxalate | Tablets Naftidrofuryl is an option for the treatment of intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking into account other treatment options. See NICE TA223: Peripheral Arterial Disease. |
| 01.06.06 | Naloxegol Moventig® | Tablets
|
| 04.10.01 | Naltrexone | Tablets |
| 04.10.03 | Naltrexone | Specialist initiation only |
| 10.01.01 | Naproxen | Tablets |
| 06.01.02.03 | Nateglinide Starlix® | Tablets |
| 02.04 | Nebivolol Nebilet® | Tablets Highly cardio-selective. Can be considered in patients with severe COPD or asthma, when benefits of beta-blockade are thought to outweigh the respiratory risks, under specialist supervision with PEFR monitoring in hospital. Can also be tried in patients who develop wheeze with less cardioselective beta-blockers. Usual to start at 1.25mg and uptitrate. This will involve the use of quarter of a 5mg tablet. |
| 11.04.02 | Nedocromil Rapitil® | Eye drops |
| 04.07.01 | Nefopam | Tablets Only to be used in those patients with moderate to severe chronic liver disease who require analgesia stronger than paracetamol in whom NSAIDS and moderate strength opiates are contraindicated |
| 09.04 | Neocate Active | |
| 09.04.02 | Neocate Advance | Dose calculated by dietitian |
| 09.04 | Neocate LCP | Dose dependent on age |
| 09.04 | Neocate Spoon | Dose dependent on age |
| 05.01.04 | Neomycin Sulphate | Tablets |
| 12.01.01 | Neomycin Sulphate with corticosteroids Otosporin® | Ear drops Not on GMMMG formulary |
| 24.02 | Neonatal TPN Maintenance Extra Protein | |
| 24.02 | Neonatal TPN Start-Up Extra Protein | |
| 10.02.01 | Neostigmine | Tablets Injection (see chapter 15) |
| 15.01.06 | Neostigmine with Glycopyrronium | |
| 05.03.01 | Nevirapine Viramune® | |
| 05.05.03 | Niclosamide | Tabletsunlicensed |
| 02.06.03 | Nicorandil Ikorel® | Tablets Indicated for stable angina only in patients whose angina is inadequately controlled by first-line anti-anginal therapies, or who have a contra-indication or intolerance to first-line therapies, such as beta-blockers and/or calcium channel blockers. |
| 04.10.02 | Nicotine Nicorette® | Patch (16 hour) Chewing gum S/L tablets Inhalator |
| 04.10.02 | Nicotine Nicotinell® | Patch (24 hour) Lozenge |
| 02.06.02 | Nifedipine | Modified release capsules Standard release capsules Raynauds phenomenon. Not recommended for angina prophylaxis or hypertensionSpecify the brand when prescribing a modified release nifedipine preparation. Short-acting formulations of nifedipine are not recommended for angina or long-term management of hypertension; their use may be associated with large variations in blood pressure and reflex tachycardia. (BNF) |
| 07.01.03 | Nifedipine | Capsules Unlicensed indication |
| 02.06.02 | Nimodipine Nimotop® | Tablets Intravenous Infusion For prevention (oral) and treatment (IV) of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage. |
| 04.01.01 | Nitrazepam | Tablets Oral suspension |
| 05.01.13 | Nitrofurantoin | Tablets Capsules M/R capsules Oral Suspension |
| 15.01.02 | Nitrous oxide | |
| 02.07.02 | Noradrenaline / Norepinephrine | Injection (for intravenous infusion; dilute before use). |
| 06.04.01.02 | Norethisterone | Tablets |
| 07.03.02 | Norgeston® Levonorgestrel 30mcg | |
| 07.03.02 | Noriday® Norethisterone 350mcg | |
| 07.03.01 | Norimin® Ethinylestradiol 35 mcg / noresthisterone 1mg | Standard strength preparation |
| 14.05.01 | Normal immunoglobulin for Intravenous use Vigam® | Established patients only |
| 14.05.01 | Normal immunoglobulin for Intravenous use Octagam® | |
| 14.05.01 | Normal immunoglobulin for subcutaneous or intramuscular use Subgam® |
See Public Health England (PHE) Guidance for full details |
| 04.03.01 | Nortriptyline | Tablets |
| 06.01.05 | Nortriptyline | Tabletsunlicensed Useful if the patient gains benefit from amitriptyline but experiences side/adverse effects |
| 06.01.01.02 | NovoMix® 30 Biphasic Insulin Aspart | 3ml cartridge (via Novopen® 4 device) 3ml prefilled disposable pen (Flexpen®) |
| 06.01.01.01 | NovoRapid® Insulin Aspart | 3ml cartridge (via Novopen® devices) 3ml prefilled disposable pen (Flexpen®) |
| 09.04 | Nutriprem 2 | Dose dependent on age |
| 09.04 | Nutriprem Hydrolysed | Dose dependent on age |
| 07.03.01 | NuvaRing® Ethinylestradiol / etonogestrel | Low strength vaginal ring |
| 12.03.02 | Nystatin Nystan® | Oral suspension |
| 13.10.02 | Nystatin Cream | Cream |
| 13.10.02 | Nystatin with Chlorhexidine cream Nystaform® | Cream |
| 08.02.03 | Obinutuzumab Gazyvaro® | Concentrate for intravenous infusion Specialist use only; for previously untreated chronic lymphocytic leukaemia (CLL) in patients with comorbidities making them unsuitable for full-dose fludarabine-based therapy |
| 24.03 | Obinutuzumab IV Infusion | |
| 08.03.04.03 | Octreotide | Solution for injection (various forms) Depot injection (Sandostatin LAR®)
|
| 07.02.01 | Oestrogens, Topical Vagifem® | Vaginal tablets |
| 07.02.01 | Oestrogens, Topical Gynest® | 0.01% intravaginal cream |
| 08.02.03 | Ofatumumab Arzerra® | Concentrate for intravenous infusion Specialist use only; CDF criteria must be met & funding approval received. |
| 24.03 | Ofatumumab IV Infusion | |
| 05.01.12 | Ofloxacin | Tablets (Intravenous infusion is non-formulary) |
| 11.03.01 | Ofloxacin Eye drops | Eye drops |
| 13.02.01 | Oilatum® | Cream |
| 13.02.01.01 | Oilatum® Bath Additive | |
| 13.02.01.01 | Oilatum® Plus emollient bath additive | |
| 13.02.01.01 | Oilatum®Plus Bath Additive | |
| 01.07.03 | Oily Phenol Injection BP | Specialist administration only |
| 04.02.01 | Olanzapine | Tablets Orodispersible tablets |
| 12.01.03 | Olive Oil Ear Drops | Ear drops |
| 11.04.02 | Olopatadine Opatanol® | Eye drops |
| 01.05.01 | Olsalazine | Capsules Tablets Specialist initiation only |
| 03.04.02 | Omalizumab Xolair® | Subcutaneous injection |
| 05.03.03.02 | Ombitasvir/Paritaprevir/Ritonavir Viekirax® 12.5mg/75mg/50mg | Tablets Requires MDT discussion with ID team |
| 02.12 | Omega-3-Acid Ethyl Esters | Capsules Should only be used for the treatment of hypertriglyceridaemia under the care of a lipid management specialist. Omega-3-Acid Ethyl Esters are NOT recommended for the secondary prevention of Myocardial Infarction. See GMMMG IPNTS recommendation. |
| 01.03.05 | Omeprazole | Capsules Injection Only for use in ventilated patients to prevent ventilator associated pneumonia and in patients who have received an endoscopic intervention for upper gastro-intestinal bleeding.Swallowing difficulties: Patients can open the capsule and swallow the contents with half a glass of water or mix the contents in fruit juice or non-carbonated water. Patients should be advised that the dispersion should be taken within 30 minute and always be stirred just before drinking and rinsed down with half a glass of water. |
| 04.06 | Ondansetron | Tablets Injection Oral lyophilisates (’melts’) Suppositories For exceptional use in non-oncology patients with chronic emesis following consultant recommendation and where all other options have failed |
| 04.06 | Ondansetron | Tablets Oral lyophilisates ('melts') Injection Suppositories |
| 04.09.01 | Opicapone Ongentys® | Capsules |
| 06.01.06 | Oral glucose tolerance test. | |
| 09.02.01.02 | Oral Rehydration Salts e.g. Dioralyte® | Oral powder |
| 04.05.01 | Orlistat | |
| 04.09.02 | Orphenadrine | Tablets Oral liquid |
| 05.03.04 | Oseltamivir Tamiflu® | Capsules Oral Suspension |
| 09.04.02 | Osmolite | 500ml 1000ml 1500ml |
| 09.04.02 | Osmolite 1.5kcal | 500ml 1000ml 1500ml |
| 09.04.02 | Osmolite HP | |
| 09.04.02 | Osmolite PLUS | 500ml 1000ml 1500ml |
| 07.03.01 | Ovysmen® Ethinylestradiol 35 mcg / noresthisterone 500mcg | Standard strength preparation |
| 04.01.02 | Oxazepam | |
| 04.08.01 | Oxcarbazepine | Tablets |
| 11.07 | Oxybuprocaine Hydrochloride Minims® | Single-use eye drops |
| 07.04.02 | Oxybutynin | Tablets M/R tablets Patches ( only when the oral route is not tolerated) |
| 04.07.02 | Oxycodone | Immediate-release preparations (OxyNorm®): M/R preparations (OxyContin®): |
| 05.01.03 | Oxytetracycline | Tablets |
| 13.06.02 | Oxytetracycline | Tablets First choice for acne and rosacea |
| 07.01.01 | Oxytocin Syntocinon® | Injection |
| 09.04 | Paediasure 200ml Bottle | |
| 09.04.02 | Paediasure 500ml Bag | Dose calculated by dietitian |
| 09.04 | Paediasure Fibre 200ml Bottle | Dose dependent on age |
| 09.04.02 | Paediasure Fibre 500ml Bag | Dose calculated by dietitian |
| 09.04 | Paediasure Peptide 200ml Bottle | |
| 09.04.02 | Paediasure Peptide 500ml Bag | Dose calculated by dietitian |
| 09.04 | Paediasure Plus 200ml Bottle | Dose dependent on age |
| 09.04.02 | Paediasure Plus 500ml Bag | Dose calculated by dietitian |
| 09.04 | Paediasure Plus Fibre 200ml Bottle | |
| 09.04.02 | Paediasure Plus Fibre 500ml Bag | Dose calculated by dietitian |
| 09.04 | Paediasure Plus Juice 200ml Bottle | |
| 05.03.05 | Palivizumab Synagis® | Injection |
| 04.06 | Palonosetron Aloxi® | Approved for emesis following breast cancer chemotherapy (2nd line after ondansetron) |
| 05.01.09 | P-aminosalicylic acid Paser® | Sachetsunlicensed Can only be prescribed following discussion with an ID physician |
| 01.09.04 | Pancreatin Creon® 10000 | |
| 01.09.04 | Pancreatin Pancrex V® | For administration via enteral feeding tubes |
| 01.09.04 | Pancreatin Creon® 40000 | |
| 01.09.04 | Pancreatin Creon® Micro | |
| 01.09.04 | Pancreatin Creon® 25000 | |
| 15.01.05 | Pancuronium Bromide | |
| 04.07.01 | Paracetamol | Tablets Soluble tablets Oral suspension Suppositories IV infusion |
| 04.07.01 | Paracetamol and codeine Co-codamol® 8/500 | Tablets Effervescent tablets |
| 04.07.01 | Paracetamol and codeine Co-codamol® 30/500 | Tablets Effervescent tablets |
| 04.07.01 | Paracetamol and dihydrocodeine Co-dydramol® 10/500 | Tablets |
| 04.08.02 | Paraldehyde Enema | Paediatric use only |
| 15.01.04.02 | Parecoxib Dynastat® | |
| 09.03 | Parenteral Nutrition (TPN) | See Chapter 24 for full list of TPN bags available. Please see Appendix 3 of attached link for details on out-of-hours TPN use |
| 04.03.03 | Paroxetine | Tablets Oral suspension |
| 09.01.06 | Pegfilgrastim Neulasta® | Injection |
| 05.03.03.01 | Peginterferon Alfa | Injection |
| 05.03.03.02 | Peginterferon Alfa | Injection |
| 08.02.04 | Peginterferon Alfa Pegasys® | First line choice for chronic hepatitis C |
| 08.02.04 | Peginterferon Alfa ViraferonPeg® | For chronic hepatitis C patients >120kg in weight. |
| 09.08.01 | Penicillamine | Tablets |
| 10.01.03 | Penicillamine | Tablets |
| 11.03.01 | Penicillin G | Eye drops unlicensed special |
| 05.04.05 | Pentamidine Isetionate | Injection |
| 05.04.08 | Pentamidine Isetionate | Injection |
| 24.01 | Pentamidine IV Infusion | |
| 24.03 | Pentostatin IV Infusion | |
| 02.06.04 | Pentoxifylline Trental® | Tablets For alcoholic liver disease. Not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease, but patients currently taking pentoxifylline should have the option to continue until they and their clinican considers it appropriate to stop. (NICE TA223:Peripheral Arterial Disease) |
| 01.02 | Peppermint Oil e/c capsules | |
| 09.04 | Pepti Junior Cow and Gate | Dose dependent on age |
| 04.08.01 | Perampanel Fycompa® | Tablets |
| 04.09.01 | Pergolide | Tablets |
| 04.02.01 | Pericyazine | Tablets |
| 02.05.05.01 | Perindopril erbumine | Tablets Prescribers are reminded that perindopril should be prescribed generically. Perindopril arginine (Coversyl Arginate®) is not dose equivalent and is not included in the formulary. |
| 13.10.04 | Permethrin 1% Lyclear® Creme Rinse | INSUFFICIENT CONTACT TIME, THEREFORE NOT RECOMMENDED |
| 13.10.04 | Permethrin 5% Lyclear® Dermal Cream | Cream |
| 04.02.01 | Perphenazine | Tablets |
| 04.07.02 | Pethidine | Tablets Injection |
| 04.03.02 | Phenelzine | |
| 02.08.02 | Phenindione | Tablets |
| 02.08.02 | Phenindione | Tablets |
| 04.08.01 | Phenobarbital | Tablets Elixir Injection Ensure patients are maintained on a specific manufacturer's product / brand |
| 04.08.02 | Phenobarbital Injection | |
| 02.05.04 | Phenoxybenzamine Hydrochloride | Capsules (Injection is non-formulary) |
| 05.01.01.01 | Phenoxymethylpenicillin | Tablets Oral Solution |
| 02.05.04 | Phentolamine Rogitine® | Injection For hypertensive episodes due to phaeochromocytoma, e.g. during surgery (BNF). |
| 02.07.02 | Phenylephrine | Injection |
| 11.05 | Phenylephrine Hydrochloride Minims® Phenylephrine Hydrochloride | 2.5% and 10% Single-use eye drops |
| 04.08.01 | Phenytoin | Capsules Suspension 30mg/5mL Chewable tablets Injection Ensure patients are maintained on a specific manufacturer's product / brand |
| 04.08.02 | Phenytoin Injection |  See loading doses policy |
| 03.09.01 | Pholcodine | Oral solution |
| 09.05.02.01 | Phosphate effervescent tablets Phosphate-Sandoz® | |
| 09.05.02.01 | Phosphate Polyfusor® | 500ml Polyfusor |
| 01.06.05 | Phosphates (oral) Fleet Phospho-soda® | |
| 01.06.04 | Phosphates Enema | |
| 09.06.06 | Phytomenadione | 1ml amps (Konakion®MM) 0.2ml amps (Konakion®MM Paediatric) - may be given orally |
| 11.06 | Pilocarpine | 1%, 2%, 4% eye drops 2% single-use eye drops (Minims®) |
| 13.05.03 | Pimecrolimus 1% Cream Elidel® | Cream Consultant Dermatologist only, in line with NICE Guidance
|
| 04.02.01 | Pimozide | Tablets |
| 06.01.02.03 | Pioglitazone Actos® | Tablets |
| 24.01 | Piperacillin / Tazobactam IV Infusion | 4.5gram in 100mL sodium chloride 0.9% |
| 05.01.01.04 | Piperacillin and Tazobactam | Injection |
| 04.02.02 | Pipotiazine Palmitate Piportil® | |
| 10.03.02 | Piroxicam gel | Gel |
| 05.01.01.05 | Pivmecillinam Hydrochloride Selexid® | Tablets |
| 24.03 | Pixantrone IV Infusion | |
| 04.07.04.02 | Pizotifen | Tablets |
| 14.04 | Pneumococcal vaccine Prevenar 13® | |
| 14.04 | Pneumococcal vaccine | Previously known as Pneumovax II® |
| 13.07 | Podophyllotoxin Condyline®or Warticon® | |
| 09.04 | Polycal | Dose calculated by dietitian |
| 06.01.06 | Polycal® | |
| 13.10.01.01 | Polyfax® Ointment | Ointment |
| 14.04 | Polysaccharide vaccine for injection Typhim Vi® | |
| 09.02.01.01 | Polystyrene Sulphonate Resins Calcium Resonium® | Powder |
| 13.09 | Polytar AF® | Shampoo |
| 13.09 | Polytar® | Liquid |
| 11.08.01 | Polyvinyl Alcohol Liquifilm Tears or Sno Tears® | Eye drops Brand with lowest aquisition cost will be supplied. |
| 08.02.04 | Pomalidomide | Capsules |
| 03.05.02 | Poractant Alfa Curosurf® | Suspension Specialist neonatal use only |
| 05.02.01 | Posaconazole Noxafil® | Suspension Tablets Specialist (haematology) or ID consultant initiation only. See linksFor AML inpatients only. Not to be supplied on discharge |
| 11.99.99.99 | Potassium Ascorbate | Eye dropsunlicensed |
| 09.02.01.01 | Potassium Chloride Kay-Cee-L® | Syrup |
| 09.02.01.01 | Potassium Chloride Sando-K® | Effervescent tablets |
| 09.02.02.01 | Potassium Chloride 0.15% and Glucose 10% Intravenous Infusion | 500ml bag (contains 10mmol of potassium)Unlicensed special - manufactured to order and may not always be available |
| 09.02.02.01 | Potassium Chloride 0.15% and Glucose 5% Intravenous Infusion | 500ml bag (contains 10mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.15% and Sodium Chloride 0.9% Intravenous Infusion | 500ml bag (contains 10mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.15%, Sodium Chloride 0.18% and Glucose 4% Intravenous Infusion | 500ml bag (contains 10mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.15%, Sodium Chloride 0.45% and Glucose 5% Intravenous Infusion | 500ml bag (contains 10mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.3% and Glucose 10% Intravenous Infusion | 500ml bag (contains 20mmol of potassium)Unlicensed special - manufactured to order and may not always be available |
| 09.02.02.01 | Potassium Chloride 0.3% and Glucose 5% Intravenous Infusion | 500ml bag (contains 20mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.3% and Sodium Chloride 0.9% Intravenous Infusion | 500ml bag (contains 20mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.3%, Sodium Chloride 0.18% and Glucose 4% Intravenous Infusion | 500ml bag (contains 20mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.3%, Sodium Chloride 0.45% and Glucose 10% Intravenous Infusion | 500ml bag (contains 20mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.3%, Sodium Chloride 0.45% and Glucose 5% Intravenous Infusion | 500ml bag (contains 20mmol of potassium)Unlicensed special - manufactured to order and may not always be available |
| 09.02.02.01 | Potassium Chloride 0.3%, Sodium Chloride 0.9% and Glucose 5% Intravenous Infusion | 500ml bag (contains 20mmol of potassium) |
| 09.02.02.01 | Potassium Chloride 0.6% and Glucose 5% | 500ml bag (contains 40mmol of potassium)Unlicensed special - manufactured to order and may not always be available 500ml bags containing 40mmol of potassium may be kept as stock in critical care areas. They will be supplied from the Pharmacy department to other wards on a named patient basis only. |
| 09.02.02.01 | Potassium Chloride 0.6% and Sodium Chloride 0.9% | 500ml bag (contains 40mmol of potassium)Unlicensed special - manufactured to order and may not always be available 500ml bags containing 40mmol of potassium may be kept as stock in critical care areas. They will be supplied from the Pharmacy department to other wards on a named patient basis only. |
| 09.02.02.01 | Potassium Chloride 15% Concentrate BP | 10ml amps (Contains 20mmol potassium) Only the designated areas given in Appendix 1 of the Intravenous Potassium Policy have been authorised to stock and administer strong potassium chloride solutions as indicated. Potassium chloride concentrated solutions must never be transferred between clinical areas Must be stored in a Controlled Drugs cupboard. Must NEVER be administered undiluted (NPSA 'Never Event) |
| 09.02.02.01 | Potassium Chloride 3% in Sodium Chloride 0.9% | 100ml bag (contains 40mmol potassium) Only the designated areas given in Appendix 1 of the Intravenous Potassium Policy have been authorised to stock and administer strong potassium chloride solutions as indicated. Potassium chloride concentrated solutions must never be transferred between clinical areas Order as a Controlled Drug. Potassium chloride infusion 40mmol in 100ml sodium chloride 0.9% must be stored in a locked cupboard and kept separate from other infusion bags. |
| 07.04.03 | Potassium Citrate Mixture BP | Oral solution |
| 13.11.06 | Potassium Permanganate Permitabs® | Solution tablets |
| 13.11.04 | Povidone-Iodine Betadine® or Videne® | |
| 04.09.01 | Pramipexole | Tablets M/R tablets |
| 02.09 | Prasugrel Efient® | Tablets See information above, and GMMMG algorithms below. |
| 02.12 | Pravastatin | Tablets |
| 05.05.03 | PRAZIQUANTEL Tablets 500 mg | Tabletsunlicensed |
| 05.05.05 | PRAZIQUANTEL Tablets 500 mg | Tabletsunlicensed |
| 01.05.02 | Prednisolone | Tablets Soluble tablets Rectal foam Retention enema Suppositories
|
| 06.03.02 | Prednisolone | Tablets (NOT enteric coated) Soluble tablets - paediatrics only |
| 11.04.01 | Prednisolone | Eye drops (0.5% and 1%) Single use eye drops 0.5% (Minims®) |
| 04.07.03 | Pregabalin | Capsules A trial of pregabalin may be considered in patients who cannot tolerate gabapentin, or who have not responded fully despite an adequate trial. |
| 04.08.01 | Pregabalin | Capsules FOR EPILEPSY. See section 4.7.3 for use in neuropathic pain. |
| 06.01.05 | Pregabalin | Capsules A trial of pregabalin may be considered in patients who cannot tolerate gabapentin, or who have not responded fully despite an adequate trial. |
| 06.04.01.01 | Premarin® | Tablets Conjugated oestrogen 300micrograms Conjugated oestrogen 625micrograms Conjugated oestrogen 1.25mg |
| 06.04.01.01 | Premique® | Tablets Conjugated oestrogen 625micrograms + medroxyprogesterone acetate 5mg |
| 06.04.01.01 | Premique® low dose | Tablets Conjugated oestrogen 300micrograms + medroxyprogesterone acetate 1.5mg |
| 06.04.01.01 | Prempak-C® | Tablets Conjugated oestrogens 625micrograms + norgestrel 150micrograms Conjugated oestrogens 1.25mg + norgestrel 150micrograms |
| 05.04.01 | Primaquine | Tablets |
| 05.04.08 | Primaquine | Tablets |
| 04.08.01 | Primidone | Tablets Ensure patients are maintained on a specific manufacturer's product / brand |
| 04.09.03 | Primidone | Tablets |
| 10.01.04 | Probenecid | Tabletsunlicensed |
| 09.04 | Procal | Dose calculated by dietitian |
| 04.06 | Prochlorperazine | Tablets Buccal tablets (Buccastem®) Syrup Injection |
| 04.06 | Prochlorperazine | Tablets Buccal tablets (Buccastem®) Syrup Injection |
| 04.06 | Prochlorperazine | Tablets Buccal tablets (Buccastem®) Syrup Injection |
| 04.09.02 | Procyclidine | Tablets Syrup Injection |
| 13.10.05 | Proflavine Cream, BPC | Cream |
| 06.04.01.02 | Progesterone Cyclogest® | Pessaries/suppositories "Red" when used for infertility |
| 06.04.01.02 | Progesterone Gestone® | Injection |
| 05.04.01 | Proguanil Hydrochloride | Tablets |
| 05.04.01 | Proguanil Hydrochloride with Atovaquone Malarone® | Tablets |
| 04.02.01 | Promazine Hydrochloride | Tablets Oral solution Only licensed for agitation |
| 03.04.01 | Promethazine | Tablets Elixir Injection |
| 04.01.01 | Promethazine Hydrochloride | Tablets Elixir Injection |
| 04.06 | Promethazine Hydrochloride | Tablets Elixir Injection |
| 04.06 | Promethazine Hydrochloride | Tablets Elixir Injection |
| 02.03.02 | Propafenone | |
| 11.03.01 | Propamidine Isetionate Brolene® | Eye drops Used with chlorhexidine for treatment of acanthamoeaba keratitis only |
| 15.01.01 | Propofol | |
| 02.04 | Propranolol | Tablets Modified Release Capsules Liquid |
| 04.07.04.02 | Propranolol | Tablets M/R capsules Oral solution |
| 04.09.03 | Propranolol | Tablets M/R capsules Oral solution |
| 06.02.02 | Propylthiouracil | Tablets Prescribing to remain with specialist care until stable. |
| 02.08.03 | Protamine Sulphate | Injection |
| 05.01.09 | Prothionamide | Tabletsunlicensed Can only be prescribed following discussion with an ID physician |
| 11.07 | Proxymetacaine Hydrochloride Minims® | Single-use eye drops |
| 01.06.07 | Prucalopride Resolor® | Tablets
Initial 2-weeks supply from hospital
|
| 03.10 | Pseudoephedrine Hydrochloride | Tablets Elixir |
| 13.05.02 | Psoriderm® Coal tar 6% | Cream |
| 05.01.09 | Pyrazinamide | Tablets |
| 10.02.01 | Pyridostigmine Bromide | Tablets |
| 05.01.09 | Pyridoxine | Tablets |
| 09.06.02 | Pyridoxine Hydrochloride | Tablets Injection Oral Solution unlicensed |
| 05.04.01 | Pyrimethamine | Tablets |
| 05.04.07 | Pyrimethamine | Tablets |
| 04.02.01 | Quetiapine | Tablets M/R tablets |
| 05.04.01 | Quinine | Tablets Injection |
| 10.02.02 | Quinine Sulphate | Tablets |
| 13.02.01 | QV® | Skin lotion Cream Intensive ointment Only on advice of tissue viability |
| 13.02.01.01 | QV® | Bath oil Gentle wash Only on advice of tissue viability |
| 14.05.02 | Rabies Immunoglobulin | Medical team to contact Clinical Virology at Central Manchester Foundation Trust (0161 276 8853) |
| 14.04 | Rabies vaccine | Pre-exposure vaccination: NMGH Travel Clinic only |
| 06.04.01.01 | Raloxifene Hydrochloride Evista® | Tablets |
| 05.03.01 | Raltegravir Isentress ® | |
| 02.05.05.01 | Ramipril | Capsules |
| 11.08.02 | Ranibizumab Lucentis® | Intravitreal injection Ophthalmic consultant only Use as per GMMMG Macular Drugs Pathway |
| 01.03.01 | Ranitidine | Tablets Effervesent tablets Syrup Injection |
| 02.06.03 | Ranolazine Ranexa® | Tablets Restricted to cardiac services (PAHT) For stable angina where patients are unsuitable for physical therapy or first and second line agents (PAHT). |
| 10.01.04 | Rasburicase Fastertec® | Intravenous infusion |
| 04.03.04 | Reboxetine | |
| 15.01.04.03 | Remifentanil Ultiva® | |
| 06.01.02.03 | Repaglinide Prandin® | Tablets |
| 04.08.01 | Retigabine | Tablets |
| 05.03.03.02 | Ribavirin Copegus® | Tablets |
| 05.01.09 | Rifabutin Mycobutin® | Capsules Can only be prescribed following discussion with an ID Physician |
| 05.01.09 | Rifampicin | Capsules Tablets Syrup Intravenous Infusion No restrictions on use for non-tuberculosis indications. |
| 05.01.09 | Rifampicin and Isoniazid Rifinah® | Tablets For continuation (maintenance) phase of treatment |
| 05.01.09 | Rifampicin and Isoniazid and Pyrazinamide Rifater® | Tablets 2nd line option with a 4th agent |
| 05.01.09 | Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv® | Tablets |
| 05.01.07 | Rifaximin | Gastroenterologists only Initial 2 weeks supply provided by secondary care. |
| 05.03.01 | Rilpivirine hydrochloride Edurant® | |
| 04.09.03 | Riluzole | Tablets |
| 11.04.01 | Rimexolone Vexol® | Eye drops |
| 06.06.02 | Risedronate | 35mg tablets (once weekly preparation) |
| 04.02.01 | Risperidone | Tablets Orodispersible tablets Liquid |
| 04.02.02 | Risperidone Risperdal Consta® | |
| 05.03.01 | Ritonavir Norvir® | |
| 08.02.03 | Rituximab MabThera® | Concentrate for intravenous infusion Specialist use only |
| 10.01.03 | Rituximab | Intravenous Infusion |
| 24.03 | Rituximab IV Infusion | |
| 24.03 | Rituximab SC Injection | |
| 02.08.02 | Rivaroxaban Xarelto® | Tablets |
| 02.08.02 | Rivaroxaban Xarelto® | Tablets |
| 02.08.02 | Rivaroxaban Xarelto® | Tablets |
| 04.11 | Rivastigmine | Capsules Oral solution Patch Commissioning arrangements may vary and in some localities this is Green2 - check with relevant CCG |
| 15.01.05 | Rocuronium Bromide Esmeron® | |
| 03.03.03 | Roflumilast Daxas® | Tablets |
| 09.01.04 | Romiplostim Nplate® | Injection PbR excluded - commissioned by CCG Prescribers need to ensure manufacturer makes romiplostim available with the discount agreed as part of the patient access scheme. |
| 04.09.01 | Ropinirole | Tablets M/R tablets |
| 02.12 | Rosuvastatin | Tablets Approved for use in PAHNT for patients who have not achieved target levels with other statins. |
| 14.04 | Rotavirus vaccine Rotarix® | |
| 04.09.01 | Rotigotine Patch | Only for patients unable to tolerate or comply with oral medication. |
| 04.08.01 | Rufinamide | |
| 04.09.01 | Safinamide Xadago | Tablet |
| 03.01.01.01 | Salbutamol | Dry powder inhaler (DPI)(Easyhaler®) Breath-actuated inhaler (Airomir® Autohaler, Salamol Easi-breathe®) Dry powder inhaler(Ventolin®Accuhaler) |
| 03.01.01.01 | Salbutamol | Inhalers (see separate entries) Nebuliser solution Tablets Oral solution Injection Solution for infusion The use of short-acting adrenoreceptor agonists for tocolyis in premature labour has been restricted to 48 hours maximum parenteral use under specialist supervision, after a European safety review (MHRA 2013 - see Drug Safety Update) |
| 03.01.01.01 | Salbutamol | Brands include Ventolin Evohaler®, Airomir® inhaler. |
| 07.01.03 | Salbutamol | Injection |
| 13.07 | Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol®or Duofilm® | Paint |
| 01.01 | Salicylic Acid Ointment | Ointment |
| 13.10.02 | Salicylic Acid Ointment | Ointment |
| 03.01.01.01 | Salmeterol | Metered dose inhaler 25 micrograms/dose (Serevent Evohaler®) Dry powder inhaler (Serevent Accuhaler®) |
| 09.06.07 | Sanatogen A-Z | Tablets |
| 10.01.03 | Sarilumab Kavzara® | Pre-filled syringe or pen |
| 24.03 | Savene IV Infusion | |
| 06.01.02.03 | Saxagliptin Onglyza® | Tablets For established patients only. Alogliptin is first line. |
| 01.07.02 | Scheriproct® | Ointment Suppositories |
| 13.05.02 | Sebco® | Scalp Ointment |
| 10.01.03 | Secukinumab Cosentyx® | Pre-filled syringe |
| 13.05.03 | Secukinumab Cosentyx® | |
| 04.09.01 | Selegiline Hydrochloride | Tablets |
| 13.09 | Selenium Sulphide 2.5% Shampoo Selsun® | Shampoo |
| 01.06.02 | Senna | Tablets Syrup |
| 04.03.03 | Sertraline | Tablets |
| 09.05.02.02 | Sevelamer Hydrochloride Renagel® | Tablets |
| 15.01.02 | Sevoflurane | |
| 02.05.01 | Sildenafil | Tablets (Revatio®) Suspension (paediatric use) unlicensedFormulary for treatment of pulmonary arterial hypertension. For erectile dysfunction, see chapter 7.4.5. |
| 07.04.05 | Sildenafil | Tablets |
| 13.07 | Silver Nitrate 95% with Potassium Nitrate 5% AVOCA® | Caustic Applicator (stick) |
| 13.10.01.01 | Silver Sulfadiazine 1% Cream Flamazine® | Cream |
| 05.03.03.02 | Simeprevir Olysio® | Requires MDT discussion with ID team For resistant cases only |
| 01.01.01 | Simeticone infacol® | |
| 09.04 | Similac alimentum | Dose dependent on age |
| 09.04 | Similac High Energy | Dose dependent on age |
| 03.09.02 | Simple Linctus, BP | Oral solution |
| 03.09.02 | Simple Linctus, Paediatric BP | Oral solution |
| 02.12 | Simvastatin | Tablets |
| 13.02.02 | Siopel® | Cream |
| 06.01.02.03 | Sitagliptin Januvia® | Tablets For established patients only. Alogliptin is first line. |
| 24.02 | SMOFlipid 20% with vitamins | 50mL syringe |
| 10.01.03 | Sodium Aurothomalate Myocrisin® | Injection |
| 09.08.01 | Sodium Benzoate | |
| 07.04.03 | Sodium Bicarbonate | Capsules Tablets |
| 09.02.01.03 | Sodium Bicarbonate | Capsules Tablets |
| 09.02.02.01 | Sodium Bicarbonate Polyfusor® | 1.26% 1.4% 4.2% 8.4% |
| 09.02.02.01 | Sodium Bicarbonate | 4.2% 5ml amps unlicensed 4.2% 10ml amps unlicensed8.4% 10ml amps |
| 09.02.02.01 | Sodium Bicarbonate Minijet® | 4.2% 10ml Minijet 8.4% 10ml Minijet 8.4% 50ml Minijet |
| 12.01.03 | Sodium Bicarbonate | Ear drops |
| 09.02.01.02 | Sodium Chloride Slow Sodium® | Modified release tablets |
| 09.02.02.01 | Sodium Chloride 0.18% and Glucose 10% Intravenous Infusion | 500ml bag |
| 09.02.02.01 | Sodium Chloride 0.18% and Glucose 4% Intravenous Infusion | 500ml bag 1L bag |
| 09.02.02.01 | Sodium Chloride 0.45% and Glucose 10% Intravenous Infusion | 500ml bag |
| 09.02.02.01 | Sodium Chloride 0.45% and Glucose 5% Intravenous Infusion | 500ml bag |
| 09.02.02.01 | Sodium Chloride 0.45% Infusion | 500ml bag |
| 03.01.05 | Sodium Chloride 0.9% | Nebuliser solution |
| 13.11.01 | Sodium Chloride 0.9% | Solution |
| 09.02.02.01 | Sodium Chloride 0.9% and Glucose 5% Intravenous Infusion | 500ml bag 1L bag |
| 09.02.02.01 | Sodium Chloride 0.9% Infusion | 50ml bag 100ml bag 250ml bag 500ml bag 500ml polyfusor 1L bag |
| 09.02.02.01 | Sodium Chloride 0.9% Injection | 2ml amps 5ml amps 10ml amps 20ml amps |
| 12.02.02 | Sodium Chloride 0.9% Nose Drops | Nose drops |
| 11.08.01 | Sodium Chloride 0.9% Solutions | Single-use eye drops |
| 11.99.99.99 | Sodium Chloride 5% | Preservative-free Eye dropsunlicensed |
| 12.03.04 | Sodium Chloride Mouthwash, Compound BP | Mouthwash |
| 09.02.02.01 | Sodium Chloride Polyfusor (500ml) | 0.18% 0.9% 1.8% 2.7% 5% |
| 01.06.04 | Sodium Citrate Micro-enema® | |
| 06.06.02 | Sodium Clodronate | Tablets Specialist Initiation Only |
| 11.04.02 | Sodium Cromoglicate | Eye drops |
| 09.01.01.01 | Sodium Feredetate Sytron® | 27.5mg iron per 5ml |
| 05.01.07 | Sodium fusidate | Tablets Oral Suspension Injection ID/microbiologist recommendation only |
| 11.08.01 | Sodium Hyaluronate | Eye drops (brand with lowest aquisition cost will be supplied) 1.2% syringe (BVI OVD®) 2.5% syringe (BVI Multivisc®) |
| 02.05.01 | Sodium Nitroprusside | Intravenous infusionunlicensed |
| 09.08.01 | Sodium Phenybutyrate Ammonaps® | |
| 01.06.02 | Sodium Picosulfate | Elixir |
| 01.06.05 | Sodium Picosulfate with Magnesium Citrate Citrafleet® or Picolax® | |
| 05.04.05 | Sodium Stibogluconate Pentostam® | Injection |
| 02.13 | Sodium Tetradecyl Sulphate Fibro-Vein® | Injection |
| 04.08.01 | Sodium Valproate | Tablets (e/c) Crushable tablets M/R tablets Syrup Injection |
| 05.03.03.02 | Sofosbuvir Sovaldi® | Tablets Requires MDT discussion with ID team |
| 05.03.03.02 | Sofosbuvir / Velpatasvir Epclusa® | Tablets Requires MDT discussion with ID team |
| 05.03.03.02 | Sofosbuvir / Velpatasvir / Voxilaprevir Vosevi® | Tablets Requires MDT discussion with ID team |
| 07.04.02 | Solifenacin | Tablets |
| 02.04 | Sotalol | Tablets Specialist initiation Sotalol is an option for managing life-threatening arrhythmias. |
| 02.02.03 | Spironolactone | Tablets Suspension Spironolactone is significantly cheaper than eplerenone but there is no data available to compare cost-effectivess in particular groups of patients. |
| 13.02.02 | Sprilon® | Spray |
| 05.03.01 | Stavudine Zerit® | Capsules Oral Solution Only for patients already established on this treatment |
| 01.06.01 | Sterculia Normacol® | Granules |
| 02.10.02 | Streptokinase | Injection |
| 05.01.09 | Streptomycin Sulphate | Intramuscular Injection Can only be prescribed following discussion with an ID physician. |
| 06.06.02 | Strontium Ranelate Protelos® | Granules Specialist Initiation Only |
| 01.03.03 | Sucralfate Antepsin® | Tablets Suspension Following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying |
| 13.02.02 | Sudocrem® | Cream |
| 15.01.06 | Sugammadex Bridion® | |
| 05.01.08 | Sulfadiazine | Tablets Can only be prescribed following discussion with ID Physician. See BHIVA Guidelines |
| 05.04.07 | Sulfadiazine | Tablets Can only be prescribed following discussion with an ID physician |
| 01.05.01 | Sulfasalazine | Tablets Suspension |
| 10.01.03 | Sulfasalazine | Enteric coated tablets |
| 10.01.04 | Sulfinpyrazone | Tablets |
| 04.02.01 | Sulpiride | Tablets Oral solution |
| 04.07.04.01 | Sumatriptan | Tablets Injection |
| 04.07.04.03 | Sumatriptan | Injection |
| 13.08.01 | Sunsense® Ultra SPF 50+ | Lotion Preparations with an SPF less than 30 should not be prescribed. |
| 15.01.05 | Suxamethonium Chloride | |
| 13.09 | T/Gel® Therapeutic Shampoo Coal tar extract 2% | Shampoo |
| 13.05.02 | Tacalcitol Curatoderm® | Lotion Ointment To be commenced on advice of dermatology only |
| 08.02.02 | Tacrolimus | Capsules Granules Modified-release capsules Concentrate for intravenous infusion Prescribe by brand. Do not switch between brands.There are 3 different oral formulations of tacrolimus: |
| 13.05.03 | Tacrolimus Protopic® | 0.03% Ointment 0.1% Ointment Consultant Dermatologist only |
| 01.05.03 | Tafacitinib Xeljanz® | Tablets As per NICE TA547 following MDT discussion |
| 08.03.04.01 | Tamoxifen | Tablets |
| 07.04.01 | Tamsulosin | Capsules |
| 04.07.02 | Tapentadol SR Palexia SR® | Prolonged release tablets
|
| 05.01.07 | Teicoplanin | Injection |
| 04.01.01 | Temazepam | Tablets Oral solution |
| 15.01.04.01 | Temazepam | |
| 05.01.01.02 | Temocillin Negaban® | Intravenous injection For use in hospital-acquired UTIs in paediatrics - see policy
|
| 02.10.02 | Tenecteplase Metalyse® | Injection |
| 05.03.01 | Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla® | |
| 05.03.01 | Tenofovir alafenamide and Emtricitabine Descovy® | Requires MDT discussion with ID team |
| 05.03.01 | Tenofovir alafenamide, Emtricitabine and Rilpivirine Odefsey® | Tablet Requires MDT discussion with ID team |
| 05.03.01 | Tenofovir alafenamide, Emtricitabine, Elvitegravir and Cobicistat Genvoya® | Tablet Requires MDT discussion with ID team |
| 05.03.01 | Tenofovir and Emtricitabine Truvada® | |
| 05.03.03.01 | Tenofovir Disoproxil Viread® | |
| 05.03.01 | Tenofovir Disproxil Viread® | |
| 05.03.01 | Tenofovir, cobicistat, elvitegravir & emtricitabine Stribild® | Tablets Requires MDT discussion with ID team |
| 05.02.05 | Terbinafine | Tablets Dermatology only |
| 13.10.02 | Terbinafine 1% cream | Cream |
| 03.01.01.01 | Terbutaline | Dry powder inhaler (DPI)(Bricanyl® Turbohaler) |
| 03.01.01.01 | Terbutaline | Inhaler (see separate entry) Nebuliser solution 5mg/2ml (Respules®) |
| 07.01.03 | Terbutaline | Injection |
| 06.06.01 | Teriparatide Forsteo® | Injection 2nd line treatment for severe osteoporosis in accordance with NICE guidance. For specialist use only PbR excluded - commissioned by CCG |
| 06.05.02 | Terlipressin Glypressin® | Injection |
| 06.04.02 | Testosterone enantate | IM injection |
| 06.04.02 | Testosterone gel Testogel® | Gel |
| 06.04.02 | Testosterone gel Tostran® | Gel |
| 06.04.02 | Testosterone implant | Implant |
| 06.04.02 | Testosterone oral Restandol Testocaps® | Capsules |
| 06.04.02 | Testosterone undecanoate | IM injection |
| 14.05.02 | Tetanus immunoglobulin | Treatment of clinical tetanus: IV tetanus immunoglobulin no longer available - use IV human normal immunoglobulin (eg: Octagam® 10%) Prophylaxis of tetanus-prone wounds: There are intermittent supply problems with IM tetanus immunoglobulin - use Subgam® human normal immunoglobulin SC/IM See Public Health England (PHE) Guidance for full details
|
| 04.09.03 | Tetrabenazine | Tablets |
| 11.07 | Tetracaine Hydrochloride Minims® Amethocaine Hydrochloride | Single-use eye drops |
| 06.05.01 | Tetracosactide Synacthen® | 250 microgram/ml injection (for short 30-minute test) 1mg/ml depot injection (for 5-hour test) |
| 05.01.03 | Tetracycline | Tablets |
| 05.01.10 | Thalidomide | Tablets Approved for use by ID physicians only for patients who have steroid dependent Immune Reconsitution Syndrome (IRIS) secondary to HIV related opportunistic infection or meningeal tuberculosis in a non-HIV patient. unlicensed use |
| 08.02.04 | Thalidomide Thalidomide Celgene® | Capsules |
| 03.01.03 | Theophylline | Modified release tablets (Nuelin SA®, Uniphyllin Continus®)
|
| 09.06.02 | Thiamine | Tablets |
| 05.01.09 | Thioacetazone | unlicensed Can only be prescribed following discussion with an ID physician |
| 15.01.01 | Thiopental | |
| 24.03 | Thiotepa IV Infusion | |
| 05.05.07 | TIABENDAZOLE 500mg tabs | Tabletunlicensed |
| 04.08.01 | Tiagabine | Tablets |
| 06.04.01.01 | Tibolone Livial® | Tablets |
| 02.09 | Ticagrelor Brilique® | Tablets See information above. Only to be prescribed on advice of cardiology |
| 05.01.01.04 | Ticarcillin with Clavulanic Acid Timentin® | Injection |
| 14.04 | Tick-borne encephalitis vaccine | NMGH Travel Clinic only |
| 05.01.03 | Tigecycline | Intravenous Infusion Can only be prescribed following discussion with the Consultant Microbiologist or ID Physician |
| 11.06 | Timolol | Eye drops Unit dose eye drops Long acting gel drops (Timolol LA®) |
| 05.01.11 | Tinidazole Fasigyn® | Tablets |
| 05.04.02 | Tinidazole | See section 5.1.11 |
| 03.01.02 | Tiotropium Spiriva® | Inhalation powder, hard capsule for use with Handihaler® device, 18 micrograms. Respimat® inhaler 2.5 micrograms/dose. The Spiriva Respimat device should be used with caution in patients with known cardiac rhythm disorders - see SPC |
| 03.01.04 | Tiotropium / Olodaterol Spiolto® Respimat | Metered dose inhaler Combination LABA/LAMA inhaler |
| 05.03.01 | Tipranavir Aptivus® | |
| 02.09 | Tirofiban Aggrastat® | Concentrate for infusion |
| 10.02.02 | Tizanidine | Tablets |
| 05.01.04 | Tobramycin | Injection Dry powder inhaler ("'Podhaler'") Nebuliser solution Can only be prescribed for intravenous use following discussion with the Consultant Microbiologist or ID Physician Injection solution can be nebulised in non-CF bronchiectasis; at the request of a Consultant Respiratory Physician only |
| 24.01 | Tobramycin IV infusion | 240mg ECLIPSE pump |
| 10.01.03 | Tocilizumab | Intravenous preparation ONLY (Subcutaneous preparation is currently non-formulary) |
| 24.03 | Tocilizumab IV Infusion | |
| 10.01.03 | Tofacitinib Xeljanz | Tablets |
| 07.04.02 | Tolterodine | Tablets M/R capsules |
| 06.05.02 | Tolvaptan Samsca® | Tablets |
| 04.07.04.02 | Topiramate | Tablets Sprinkle® capsules  Topiramate hard capsules are expensive and should not be prescribed. For those patients unable to swallow topiramate tablets “sprinkle capsules” may be considered |
| 04.08.01 | Topiramate | Tablets Sprinkle® capsules Topiramate hard capsules are expensive and should not be prescribed. For those patients unable to swallow topiramate tablets “sprinkle capsules” may be considered |
| 02.02.02 | Torasemide | Tablets |
| 06.01.01.02 | Toujeo® Insulin Glargine 300units/mL | 1.5ml prefilled disposable pen (Solostar®) **HIGH-STRENGTH INSULIN PRODUCT** See guidance below
|
| 04.07.02 | Tramadol | Capsules Soluble tablets M/R tablets or capsules Injection |
| 02.11 | Tranexamic Acid | Tablets Injection |
| 12.03.04 | Tranexamic Acid Mouthwash | unlicensed |
| 10.03.02 | Transvasin | Heat rub cream |
| 04.03.02 | Tranylcypromine | |
| 11.06 | Travoprost Travatan® | Eye drops Does not contain benzalkonium chloride as the preservative and therefore may be used in patients where a known allergy to benzalkonium chloride exists. |
| 11.06 | Travoprost with Timolol DuoTrav® | Eye drops Does not contain benzalkonium chloride as the preservative and therefore may be used in patients where a known allergy to benzalkonium chloride exists. Combination products are licensed for once daily use where prostaglandin analogue alone is not adequate. Only use where patient has difficulty with compliance/administration. |
| 04.03.01 | Trazodone | Capsules Tablets Liquid |
| 06.01.01.02 | Tresiba® Insulin degludec | 3ml cartridges (via Novo Nordisk® devices) 3ml pre-filled disposable pen (Flextouch®) **Only the 100units/mL strength has been approved by the Division of Medicine. Use of the 200units/ml strength requires named-patient approval from Medical D&T Committee Chair** |
| 06.03.02 | Triamcinolone Kenalog® | Injection |
| 10.01.02.02 | Triamcinolone Acetonide | Injection |
| 13.04 | Triamcinolone Acetonide 0.1% with Chlortetracycline Hydrochloride 3% Aureocort® | Ointment |
| 13.07 | Trichloroacetic Acid | Solution |
| 13.11.05 | Triclosan 2% Aquasept® | Usage has been replaced by Hibiscrub |
| 04.02.01 | Trifluoperazine | Tablets Oral solution 5mg/5mL Syrup 1mg/5mL |
| 04.09.02 | Trihexyphenidyl | Tablets Syrup |
| 05.01.08 | Trimethoprim | Tablets Oral Suspension |
| 05.01.13 | Trimethoprim | See section 5.1.8. |
| 07.03.01 | TriNovum® Ethinylestradiol / norethisterone phased pill | Tri-phasic preparation |
| 01.03.03 | Tripotassium Dicitratobismuthate De-Noltab® | H.pylori eradication only |
| 11.05 | Tropicamide Mydriacyl® | 0.5% and 1% Eye drops 0.5% and 1% single-use eye drops (Minims®) |
| 07.04.02 | Trospium | Tablets M/R capsules |
| 04.03.04 | Tryptophan | |
| 09.04.02 | Two Cal | |
| 06.04.01.02 | Ulipristal Esmya® | Tablets |
| 07.03.05 | Ulipristal EllaOne® | |
| 03.01.02 | Umeclidinium Incruse Ellipta | |
| 03.01.04 | Umeclidinium / Vilanterol Anoro® Ellipta | Combination LABA/LAMA inhaler |
| 13.02.01 | Unguentum M® | Cream Dermatology only |
| 13.11.02 | Unisept® Chlorhexidine Gluconate 0.05% | Sachets |
| 02.10.02 | Urokinase | Injection |
| 01.09.01 | Ursodeoxycholic acid | Capsules Suspension |
| 10.01.03 | Ustekinumab | Subcutaneous Injection |
| 13.05.03 | Ustekinumab | NICE and GMMMG recommend ustekinumab as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when: • treatment with TNF alpha inhibitors is contraindicated but would otherwise be considered • or the person has had treatment with 1 or more TNF–alpha inhibitors. Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment. Available via Patient Access Scheme: please contact pharmacy for details |
| 13.08.01 | Uvistat® | Cream Ultrablock Cream Preparations with an SPF less than 30 should not be prescribed. |
| 05.03.02.01 | Valaciclovir Valtrex® | Tablets Can only be prescribed on advice of ID physician or virologist |
| 05.03.02.02 | Valganciclovir Valcyte® | |
| 04.02.03 | Valproic Acid Depakote® | Tablets |
| 02.05.05.02 | Valsartan | Tablets GMMMG endorse use in post-myocardial infarction. |
| 02.05.05.02 | Valsartan / Sacubitril Entresto® | TabletsTo be initiated by Heart Failure team |
| 05.01.07 | Vancomycin | Capsules Injection
|
| 24.01 | Vancomycin IV Infusion | 500mg 750mg 1000mg 1250mg 1500mg 2000mg |
| 24.01 | Vancomycin IV Syringe for neonatal use | 40mg in 8mL sodium chloride 0.9% 80mg in 16mL sodium chloride 0.9% |
| 14.05.02 | Varicella-Zoster immunoglobulin | Medical team to contact Clinical Virology at Central Manchester Foundation Trust (0161 276 8853) |
| 14.04 | Varicella-zoster vaccine Varivax® | |
| 06.05.02 | Vasopressin Pitressin® | Injection |
| 15.01.05 | Vecuronium Bromide Norcuron® | |
| 01.05.03 | Vedolizumab Entyvio® | |
| 24.03 | Vedolizumab IV Infusion | |
| 04.03.04 | Venlafaxine | Tablets M/R tablets or capsules |
| 02.06.02 | Verapamil | Standard tablets Modified release tablets Modified release capsules Injection |
| 04.08.01 | Vigabatrin | Tablets Powder sachets |
| 24.03 | Vinblastine IV Infusion | |
| 24.03 | Vincristine IV Infusion | |
| 18 | Viper Venom antisurem | |
| 09.04.02 | Vital 1.5kcal | |
| 09.04 | Vital 1.5kcal 200ML | |
| 09.06.02 | Vitamin B Tablets (Compound) | Tablets |
| 09.06.02 | Vitamin B Tablets, Compound Strong | Tablets For the prevention of re-feeding syndrome only |
| 09.06.01 | Vitamins A and D | Capsulesunlicensed |
| 05.02.01 | Voriconazole Vfend® | Tablets Oral Suspension Intravenous Infusion Can only be prescribed following discussion with the Consultant Microbiologist, ID Physician or Haematologist |
| 02.08.02 | Warfarin | Tablets |
| 02.08.02 | Warfarin | Tablets |
| 13.02.01 | White Soft Paraffin BP | Ointment |
| 12.02.02 | Xylometazoline Otrivine® | Nasal drops |
| 01.07.02 | Xyloproct® | Ointment |
| 14.04 | Yellow fever vaccine (Live) | NMGH Travel Clinic only |
| 13.02.01 | Yellow Soft Parrafin BP | Jelly |
| 05.03.04 | Zanamivir inhalation Relenza® | Dry powder for inhalation |
| 07.03.02 | Zelleta® Desogestrel 75mcg | Tablets |
| 13.02.01 | Zerobase® | Cream |
| 05.03.01 | Zidovudine Retrovir® | Capsules Oral Solution Injection |
| 05.03.01 | Zidovudine and Lamivudine Combivir® | |
| 13.05.02 | Zinc and Salicylic Acid Paste BP Lassar's Paste | Pasteunlicensed |
| 09.05.04 | Zinc Sulphate Solvazinc® | Effervescent tablets |
| 06.06.02 | Zoledronic Acid Zometa® | Intravenous infusion For reduction of bone damage in advanced malignancies involving bone, and hypercalcaemia of malignancy |
| 06.06.02 | Zoledronic Acid Aclasta® | Intravenous infusion For: Paget's disease of bone, Postmenopausal osteoporosis ( See GMMMG NTS recommendation), and osteoporosis in men |
| 04.01.01 | Zolpidem | Tablets |
| 04.08.01 | Zonisamide | Capsules |
| 04.01.01 | Zopiclone | Tablets |
| 04.02.01 | Zuclopenthixol | Tablets |
| 04.02.01 | Zuclopenthixol Acetate injection Clopixol Acuphase® | |
| 04.02.02 | Zuclopenthixol Decanoate Clopixol® |